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ABSTRACT
Cancer is one of the leading causes of human mortality and mortality in all
diseases. There has been a boost in developing nanocarrier-based therapies for
treating cancer or other diseases during the past decade. One of the major
advantages about nanocarrier (with the size range from 1-1000 nm) lies in its
ability to specifically target tumor and maximize drug accumulation in tumor foci
through the enhanced permeability and retention effect. Advancement in
nanotechnology has opened a new paradigm in pharmaceutical field. But new
challenges have to be overcome in order to fully exploit the technology and
improve safety in clinical application.
To improve their performance, at least two types of multifunctional
nanocarriers are being developed in our lab. The first type of nanocarrier is glycol
chitosan based polymer delivery system, which is a one-step preparation system,
with excellent loading capacity. We can use the nanocarrier to guide its loading
cargo such as anticancer agents to release in a particular subcellular location, or
to load multiple drugs together to increase therapeutic efficacy. The other system
is a gold nanoparticle gated mesoporous silica hybrid system, by which we are
able to simultaneously execute multiple anticancer therapies such as the
combination of photothermal therapy and chemotherapy. Compared with the first
generation of nano-delivery system, our new nanocarrier enters cells more
efficiently through sigma 2 receptors. Moreover, it can serve as a diagnostic tool
v

through PET (Positron emission tomography), and our study shows that it is able
to detect all the spontaneously lung tumors. We believe that these multifunctional
nanocarriers have the potential benefits in various areas of current
pharmaceutical research including cancer diagnosis and treatment.
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PREFACE
Cancer is among the leading causes of human morbidity and mortality of
all the diseases worldwide. Three prevalent cancers among males are prostate
cancer, colorectal cancer and melanoma, and in females they are breast cancer,
uterine corpus and colon and rectum.1 Although during the past decades a
significant improvement has been made in extending patients’ life or even curing
some patients by chemotherapy, radiation or surgery, more efforts are still
required to fight against this life threating disease. For all the subtypes of
metastatic breast cancer and advanced pancreatic cancer, cytotoxic
chemotherapy is still the fundamental strategy.2 However, the traditional
chemotherapeutic effect is often hampered by its side effects towards some
important organs. For example, doxorubicin is a highly potent anticancer drug
used to treat solid and hematopoietic tumors, but it can cause acute cardiac
injury and chronic heart failure.3 One of the common toxic effect associated with
fluorouracil, oxaliplatin and irinotecan is hepatic steatosis with the frequency over
20%,4 and for methotrexate, cytarabine and ifosfamide they are well known for
central neurotoxic side effects.5 Besides of these side effects, the poor
pharmacokinetic parameters of some chemotherapeutical agents request for a
frequent dose and often have insufficient bioavailability in tumor. Moreover, we
are facing the complicating issues of cancer. No matter what kind of cancer or at
which stage of cancer, there are constant needs for building up a personalized
vii

therapy that has higher efficacy and less side effects. Therefore, a more
advanced and systemic therapy is unmet need.
There has been a boost in developing nanocarrier-based therapies for
treating cancer or other diseases during the past decade. One of the major
advantages about nanocarrier lies in its selectivity in tumor foci through the
enhanced permeability and retention effect (EPR, nanoparticles can
accumulation tumor tissue through the highly porous vasculature structure of
newly born tumor vessels and ineffective lymphatic drainage system).6 The first
generation of nanoformulation that enters the clinical can be categorized as
liposome, PEGylated proteins, nanocrystals, protein-drug conjugates as well as
polymer-based nanoparticles.7 The representative examples include Abraxane
(albumin-bound nanoparticles) for treating metastatic breast cancer,8 Doxil
(Doxorubicin liposome) for treating Kaposi sarcoma,9 and Zinostatin stimalamer
(polymer drug conjugates) for treating hepatocellular carcinoma. Advancement in
nanotechnology has opened a new paradigm in pharmaceutical field. But more
challenges have to be overcome in order to fully take advantage of this
nanotechnology and push it to broader clinical applications. To improve their
performance, various multifunctional nanocarriers are being developed by many
groups. By infusing the original system with higher targeting efficacy, the function
of diagnosis, higher drug-loading capacity and versatile drug-loading flexibility,
the newer generation of nanocarries tends to be more efficient and practical in
the era of personalized medicine.
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With the goal above, three strategies have been developed and applied to
improve the function of nanocarries in our thesis research. The first strategy is to
functionalize the original polymer nanoparticles for selective intracellular delivery
of drugs, which minimizes the off-target side effects. Because of specific
environmental parameters, different subcellular compartments can be selectively
targeted by specialized nanoparticles. For example, owing to the fact that
lysosomes (pH range 4.5-5)10 and cytosol and mitochondria have higher reducing
environment, different stimuli-responsive nanoparticles made from polymers or
metal particles have been designed and synthesized.11 Disulfide bond, selenium
or ferrocene and borate ester containing system were among the most popular
oxidation-responsive systems for the intracellular delivery. Here, we developed
an environment-sensitive peptide delivery system, dual secured nano-sting
(DSNS), through the combination of a zwitterionic glycol chitosan and disulfide
bonds. It released drug only if it went through an environment that had both
acidic and reducing conditions.
The second strategy we utilized is to create multifunctional nanocarriers
capable of diagnosis, therapy and therapeutic outcomes monitoring. Previous
study showed that “theranostic particles”, with their unique optical properties, can
either carry imaging molecules or acted as the imaging agent.12 In our study, we
fabricated gold nanosphere/mesoporous silica hybrid (GoMe) nanocarriers to
encapsulate either a hydrophilic drug, doxorubicin, or a hydrophobic sensitizer,
Pc 4. In the animal model study, the former nanocarrier not only showed the
potential of providing a combined chemotherapy and photothermal (PTT) therapy
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for cancer, but also demonstrated the ability of diagnosing lung cancer when
radioactive copper was incorporated; by combining PTT and photodynamic
therapy (PDT), the latter nanocarrier is able to kill cancer cells and eradicate
head and neck cancer.
The third strategy we utilized is to generate multifunctional nanocarries
with the capacity of co-delivering of different drugs. One of major advantages for
co-deliver drugs is their suppression of the notorious chermoresistance and
metastasis.13 It is of particularly importance when a systemic chemotherapy is
required for patients with middle- to late-stage of metastatic cancers. The classic
example is to co-deliver anti-metastasis and chemotherapeutic agents, where
angiogenesis inhibitor can normalize the tumor vasculature and potentiate the
co-delivered chemotherapeutic drugs.14 Especially at the low-dose of
antiangiogenic/metronomic chemotherapy, this combination can achieve
comparable efficacy but much less side effects and drug resistance.15 In the last
part of this project, we succeeded to combine the suramin, an inhibitor of VEGF
(vascular endothelial growth factor) and bFGF (basic fibroblast growth factor),
with doxorubicin in a bio-compatible polymer-based system, which partially
utilized suramin as the constructing networks and showed that the new
nanoparticle was able to improve median survival time for mice with breast
cancer lung metastasis.
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CHAPTER 1
Dual secured nano-melittin for safe and effective eradicating cancer cells1
ABSTRACT
Clinical application of natural and synthetic amphipathic peptides (e.g.,
melittin) for cancer therapy is hindered by their notorious side effect, lysing red
blood cells. To safely deliver a therapeutic peptide to the tumor tissue and kill
cancer cells, we developed an environment-sensitive peptide delivery system,
dual secured nano-sting (DSNS), through the combination of a zwitterionic glycol
chitosan and disulfide bonds. Melittin loaded DSNS could kill almost 100% of
MCF-7, HCT-116, SKOV-3, and NCI/ADR-RES (multidrug resistant) cancer cells
at the concentration of 5 µM, while not showing hemolytic effect.
INTRODUCTION
The host defense amphipathic peptides found in eukaryotic cells have
diverse activities in human and other species originating from their antibiotic,
anticancer and anti-inflammatory activities.16 These peptides oligomerize with
phospholipids in cell membrane, result in pore formation, and subsequently
cause cell death. Additionally, they act in a similar way on the membranes of
internal organelles after intracellular transport, and induce cell apoptosis.17
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Amphipathic peptides have been explored for cancer chemotherapy
because of their wide-spectrum lytic properties. Melittin is one of the most
promising amphipathic water-soluble α-helical cationic polypeptide and is derived
from toxin of honey bee Apis melllifera.18 Melittin partitions into and moves
laterally in the cell membranes as monomers, followed by oligomerization into
toroidal structures, forming pores which results in cell death.18-19 Furthermore,
most recent research showed that melittin can induce cancer cell apoptosis
through the inhibition of JAK2/STAT3 pathway.20 It is worth mentioning that
melittin also suppresses the constitutively activated NF-κB, which is partially
responsible for the development of drug resistance in cancer cells.21 It is a very
attractive cancer therapeutic agent, because cancer cells are less likely to
develop resistance to cytolytic peptides.19a, 22
Despite all of these advantages, its non-specific cytolytic activity could
lead to off-target effects such as hemolysis (lysis of red blood cells) when
administrated intravenously. Besides that, positively charged peptide could be
cleared from blood circulation rapidly by the reticuloendothelial system (RES)
system.23 Several groups developed melittin delivery systems either by
covalently fusing melittin with receptor-targeted peptide motifs or through
physically encapsulating it into liposomes or polymer nanoparticles to attenuate
its hemolytic effect while achieving therapeutic efficiency comparable to free
melittin.24 Compared with free melittin, their anticancer efficacies were
significantly decreased for the encapsulated form. Until recently, Soman et al.
developed a liposome based melittin nanocarrier (“nanobee”), which showed
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promising results in inhibiting the growth of melanoma tumors.25 Despite the
encouraging outcome of “nanobee”, they also found that “nanobee” was about
five-fold less effective as that of melittin for the tested cancer cells.
An ideal melittin carrier should be able to completely quench its hemolytic
activity while fully retaining its advantages, including wide spectrum and potent
anticancer activities. To solve this dilemma, we rationally designed a melittin
delivery system by integrating a zwitterionic glycol chitosan and disulfide bonds.
Due to its zwitterionic property, succinic anhydride modified glycol chitosan (SAGCS) shows negative surface charges at physiological pH. Positively charged
melittin can form complexes with SA-GCS through the electrostatic effect. The
complex will be further stabilized through disulfide crosslinking to yield dual
secured nano-sting (DSNS) by aerial oxidation (Figure 1.1A).
RESULTS
Functionalization of zwitterionic glycol chitosan
The zwitterionic glycol chitosan was synthesized from glycol chitosan by
acetylation with succinic anhydride. First, glycol chitosan was depolymerized by
potassium persulfate according to the literature and purified by dialysis against DI
water.26 The molecular weight or the deacetylation degree of commercial glycol
chitosan purchased from Sigma-Aldrich wasn’t strictly controlled. By
depolymerization, we were able to minimize the batch to batch difference on
molecular weight, solubility and cytotoxicity of GCS. Glycol chitosan was
depolymerized by free radical degradation with thermal dissociation initiator
potassium persulfate, which can maintain the structure integrity of glycol chitosan
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during depolymerization. The resultant molecular weights of GCS was depend on
the degradation time, a 0.5 h reduction time led to a final molecular weight of 40
kDa, and the longest degradation time (t=24 h) resulted in a 10 kDa molecular
weight. Taking into account of the advantages of solubility, cytotoxicity and
binding affinity, the resulting polymer was depolymerized for 2 h and achieved a
molecular weight of 28 kDa and PDI of 1.38 (Figure 1.2). After that, glycol
chitosan was modified according to our previously published method with
succinic anhydride (Figure 1.3).23, 27 SA-GCS showed negative surface charge at
pH 7.4, and positive surface charge at pH below its isoelectric point (IEP) (Figure
1.4B). Furthermore, the IEP of the modified glycol chitosan can be tuned by
adjusting the feeding ratio of succinic anhydride and glycol chitosan. To introduce
free thiol groups, SA-GCS was reacted with N-succinimidyl 3-[2-pyridyldithio]propionate (SPDP) and subsequently cleaved with tris(2-carboxyethyl)phosphine
(TCEP) to achieve thiolated modified glycol chitosan (SA-GCS-SH) (Figure 1.1B,
1.4A). DTNB reacted with thiol groups in GCS and generated TNB product which
was detectable at 412 nm. DTNB assay showed that each polymer chain
contains 8.7 free SH groups. The IEP of the SA-GCS slightly decreased after the
thiolation (Figure 1.4B).
To verify that zwitterionic glycol chitosan can form complexes with
positively charged melittin, we fabricated the single secure nano-sting (SSNS) by
mixing SA-GCS with melittin at pH 7.4 for 2 h at room temperature. The binding
efficiency for SA-GCS was determined by measuring the fluorescence intensity
of the tryptophan residue of melittin at λexi: 280nm, λemi: 350 nm. Fluorescence
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measurement showed that with the increase of SA-GCS polymer, the detectable
free melittin gradually decreases and achieved 100% encapsulation at the
polymer to melittin ratio (W/W) of 40 (Figure 1.5).
To further stabilize the complex, inhibit its premature release of melittin,
and eliminate its potential side effects, we substituted the SA-GCS with SC-GCSSH and aerially oxidized the complex to promote the formation of disulfide bond
among the SA-GCS-SH polymers to achieve so called dual secured nano-sting
(DSNS). Since safety is an essential requirement for melittin related delivery,
polymer to melittin ratio (W/W) of 200 was selected to ensure that no free melittin
was remaining after the formation of the complexes. The formation of DSNS was
confirmed by dynamic light scattering (DLS) (Figure 1.6) and transmission
electron microscopy (TEM) (Figure 1.7). The hydrodynamic size of SSNS (220.2
nm, PDI: 0.191) was slightly increased to 223.4 nm after oxidation (PDI: 0.161).
The size determined by DLS was larger than that obtained by TEM. This is
because TEM measured the size of solid particles while DLS measured the
hydrodynamic size of particles which includes the hydration shell surrounding a
particle. This slight size difference between SSNS and DSNS reflected the size
decrease and increase due to the formation of intra-particle and inter-particle
crosslinking, respectively. Surface charge of the both nano-complexes at pH 7.4
was slightly negative (Figure 1.8), which will help the nano-complexes escape
from the detecting of reticuloendothelial system and take advantage of the
enhanced permeability and retention effect (EPR) of tumor tissue.28 HPLC
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confirmed that no any free melittin existed in the particle suspensions of SSNS
and DSNS (Figure 1.9).
Investigate the pH responsiveness of nano-complexes by FRET
To evaluate the stability of SSNS and DSNS, Förster resonance energy
transfer (FRET) technology was employed.29 Before the fabrication of SSNS and
DSNS, melittin and zwitterionic polymer were conjugated with Sulfo-Cy5-NHS
and Cy3-NHS, respectively. Cy5-melittin was mixed with Cy3-SA-GCS and Cy3SA-GCS-SH to achieve SSNS and DSNS, respectively (Figure 1.10A). DSNS
exhibited a higher FRET signal than SSNS (Figure 1.10B) at pH 7.4, indicating
that DSNS was tighter than SSNS. To evaluate the nano-sting stability at
different pH environments, FRET signal was recorded in the pH range from 7.4 to
3.7. As the pH shifting from 7.4 to the IEPs of the polymers, the FRET intensities
of both SSNS and DSNS increased and reached maximum at the pH close to the
IEPs of the polymers, indicating the formation of more condensed nanoparticles.
Similar to other zwitterionic macromolecules, SA-GCS showed lowest solubility at
its IEP. The formation of water insoluble polymer would cause the condensation
of SSNS and DSNS, and resulted in the highest FRET signal. SA-GCS displayed
positive surface charge at pH lower than its IEP (Figure 1.4B), which would
induce the repulsion between SA-GCS and positively charged melittin, similar to
the scenario of nano-complex inside lysosome (Figure 1.1). As expected, both
SSNS and DSNS displayed reduced FRET signal when environment pH was
further decreased. At the pH of 3.7, SSNS showed a FRET intensity far less than
that at pH 7.4, indicating the dissociation of nanoparticle. By contrast, the lowest
FRET intensity DSNS reached at pH 3.7 was still higher than that of SSNS at pH
6

7.4, suggesting that the formed disulfide bonds did restrict melittin from
premature release upon the fluctuation of pH. There was one pH unit left shift of
the FRET curve from their corresponding IEPs, which we think was due to the lag
response of nano-complexes to the change in environmental pH. The dual
secured effect was also evidenced by the slower melittin release from DSNS
than SSNS, as well as more melittin released at pH 5.0 than pH 7.4 (Figure
1.11).
Investigate the hemolytic activity of nano-complexes
To validate that the combination of zwitterionic polymer coating and
disulfide crosslinking can effectively quench the hemolytic activity of melittin in
DSNS, a hemolytic assay was carried out. SSNS and DSNS were incubated with
red blood cells (RBCs) in PBS (pH 7.4) first, followed by centrifugation to
separate the intact RBCs from the released hemoglobin. As shown in Figure
1.12A, melittin lysed almost all RBCs at the concentration of 1 µM. The formation
of SSNS partially inhibited the hemolytic activity of melittin. In contrast, there was
no detectable red color in the supernatant of RBCs incubated with DSNS at the
melittin concentration of 5 µM. The hemolytic activities of SSNS and DSNS were
further quantified by UV spectrophotometer. Figure 1.12B showed that free
melittin was highly lytic to RBCs, lysed almost 100% RBCs at 2 µM, which is the
major obstacle for its clinical application. The hemolytic activity of melittin in
SSNS was significantly quenched after its complexation with zwitterionic glycol
chitosan. The residual hemolytic activity indicated that some melittin was
released when incubating with RBCs. Further stabilized through the formation of
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disulfide bonds, DSNS did not show any hemolytic activity at 2 µM and only
caused very few RBCs lyses at the concentration of 5 µM. Therefore, we proved
that SSNS was safer than free melittin, while DSNS was almost non-toxic to
RBCs up to the melittin concentration of 5 µM in pH 7.4 buffer.
To investigate the intracellular membrane lytic activity of SSNS and
DSNS, RBCs were co-incubated with melittin, SSNS, or DSNS in PBS (pH 5.0)
buffer or PBS (pH 7.4) supplemented with 10 mM glutathione (GSH) to mimic the
environments in the acidic lysosome and reducing cytosol, respectively. Acidic
pH and reducing environment quenched the hemolytic activity of melittin (Figure
1.13), which is consistent with others’ observation.30 SSNS at the concentration
of 0.5 and 1.0 µM displayed much higher hemolytic activities in acidic pH than
that in pH 7.4, suggesting the release of free melittin at low pH, which was
consistent with our FRET observation in Figure 1.10B. In contrast, because of
the restraint of disulfide bonds, acidic stimulus couldn’t trigger the release of
melittin from DSNS (Figure 1.10B), and induced only slightly more RBCs lysis
(Figure 1.13). As expected, the addition of 10 mM GSH to pH 7.4 buffer greatly
enhanced DSNS’s hemolytic activity, reached the similar level as that of SSNS at
the concentration of 2 and 5 µM (Figure 1.13). Furthermore, the hemolytic
activity of DSNS was investigated in 50% serum containing buffer to mimicking
blood. Figure 1.14 revealed that DSNS was also stable in blood simulating
buffer, not causing RBC lysis. Based on these observations, we validated that
DSNS should be safe during circulating in the blood stream while effectively
lysing intracellular organelles as illustrated in Figure 1.1.
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Cellular uptake of nano-complexes
To investigate how the stability of nano-complexes affects their cellular
uptake, confocal microscopy was employed. SSNS and DSNS were fabricated
as described above except that Cy3-SA-GSC was used instead of SA-GCS.
More red spots were detected in cells treated with DSNS than SSNS (Figure
1.15), which suggested that more DSNS nano-complexes entered cancer cells
intact than their SSNS counterparts, while some SSNS had dissociated before
endocytosis, evidenced by less Cy3 labeled SA-GCS uptake. Since DSNS was
more stable than SSNS, as shown in Figure 1.10 and further prove by Figure
1.12, DSNS won’t premature release melittin when contacting with serum protein
and red blood cell (Figure 1.15). In contrast, SSNS was only stabilized by the
electrostatic effect, which can be dissociated by the competing effect of serum
protein. Therefore, more DSNS entered cancer intact than SSNS.
Cell killing effect of nano-complexes
Due to the limitation of SSNS associated unwanted hemolytic toxicity,
further anticancer efficacy evaluation only included DSNS. NCI/ADR-RES
(OVCAR-8 Adriamycin-resistant ovarian) cancer cells were co-cultured with free
melittin and DSNS (melittin concentration of 5 µM) for 24 h.31 MTT reagent (3-(4,
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was added after that.
Living cells could convert MTT reagent into water insoluble purple crystals
(Figure 1.16A). The absence of crystals in both melittin and DSNS treated cells
indicated that the cells in both treatments were dead. To investigate the possible
mechanism of cell death, we examined the cell morphology after treatment. Cells
creanated after co-incubating with free melittin and lost its original shape (Figure
9

1.16B). In contrast to its free melittin treated counterpart, cells in Figure 1.16C
kept their intact shape after DSNS treatment. Since melittin can attack cancer
cells by forming pore structures on cell membrane 31c, we postulate that the cell
death in melittin treatment group was mainly due to the loss of cell membrane
integrity. DSNS, due to the dual-secured mechanism, could effectively enter
cancer cells (Figure 1.15) and release melittin intracellularly (Figure 1.1 and
Figure 1.13). Therefore, we postulate that DSNS treated cells were killed mainly
due to the compromised membranes of internal organelles (e.g., mitochondria).
After co-incubating with DSNS and followed by JC-1 staining, the emerging
green fluorescence signals in DSNS treated cell (Figure 1.17) confirmed that
cancer cells were killed due to mitochondria damage.
The anticancer efficacy of DSNS was further quantitatively evaluated in
four types of cancer cells, HCT-116 colon cancer cells, MCF-7 breast cancer
cells, SKOV-3 ovarian cancer cells, and NCI/ADR-RES/OVCAR-8 ovarian
(Adriamycin-resistant) cancer cells by MTT assay. As expected, both free melittin
and DSNS showed dose-dependent cytotoxicity and could kill 100% of the
cancer cells at a high dose (Figure 1.16). It is worthwhile to note that DSNS was
more effective in killing HCT-116 cells. DSNS killed 100% of HCT-116 cells at the
melittin concentration of 5 µM, at which free melittin could only kill 76% cancer
cells (Figure 1.16D). Most importantly, DSNS only showed negligible hemolytic
activity at the same concentration (Figure 1.12B). A similar anticancer effect was
observed for MCF-7 breast cancer cells and SKOV-3 ovarian cancer cells
(Figure 1.16E and 1.16F). Furthermore, we also found that DSNS killed 100% of
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Adriamycin-resistant ovarian cancer cells at the melittin concentration of 5 µM
(Figure 1.16G), which have developed multidrug resistance. Altogether, we
proved that anticancer capacity of melittin of DSNS, in contrast to other melittin
carrier systems,21, 24a was fully retained. In addition, the polymer carrier itself was
not toxic for all four tested cell lines (Figure 1.18).
DISCUSSION
In summary, we have fabricated DSNS nano-complexes through the
electrostatic absorption of zwitterionic glycol chitosan and disulfide crosslinking to
deliver melittin for cancer therapy. The hemolytic activity of melittin in DSNS
could be completely quenched by our unique dual secured design. Due to the pH
and redox potential dual responsiveness of DSNS, the wide-spectrum anticancer
activity of melittin was fully retained, eradicating 100% of four types of tested
cancer cell lines, including a drug resistant cell line. These studies demonstrated
that the combination of zwitterionic polymer and redox sensitive bonds offer a
new strategy for safe and effective therapeutic peptide delivery. The next step of
research would be adding cancer cell targeting ligands, such as folic acid,
anisamide, and disaccharide moiety of bleomycin,32 to the DSNS to further
enhance its tumor specificity.
MATERIALS AND METHODS
Materials
Glycol chitosan (GCS, Mw = 200 kDa; degree of deacetylation = 90%),
potassium persulfate, sodium borohydride, succinic anhydride, melittin from bee
venom, sodium dodecyl sulfate, D-(+)-trehalose dehydrate, N-succinimidyl 3-[2-
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pyridyldithio]-propionate (SPDP), tris(2-carboxyethyl)phosphine (TCEP), triethlyl
amine (TEA), ethylenediaminetetraacetic acid (EDTA), and dimethyl sulfoxide
(DMSO) were purchased from Sigma-Aldrich (St Louis, MO, USA). L-cysteine
HCl and Ellman’s reagent were purchased from Thermo Scientific (Rockford, IL,
USA). Dulbecco’s Modified Eagle Medium (DMEM) supplied with high glucose,
trypsin and penicillin-streptomycin were purchased from Invitrogen (Carlsbad,
CA, USA). Fetal bovine serum (FBS) was purchased from ATCC (Manassas, VA,
USA).
Depolymerization of glycol chitosan
Glycol chitosan (Mw: 200 kDa) was first depolymerized to Mw 28 kDa
using potassium persulfate, and then modified by reacting with succinic
anhydride and SPDP sequentially. Briefly; glycol chitosan (400 mg) was
dissolved in 37.5 ml of hydrochloric acid (2%, v/v). After that, potassium
persulfate (67.5 mg) was added to the above glycol chitosan solution to start the
depolymerization. The reaction was kept at 70 °C for 2 h and then stopped by
adding sodium borohydride (300 mg). The reaction mixture was neutralized with
sodium hydroxide (1 M). The resulting polymer was dialyzed (Spectra 7 MWCO:
3500 Da) against ddH2O for 24 h followed lyophilization. Molecular weight of the
polymer was obtained from GPC (Viscotek GPCmax VE 2001 GPC
solvent/sample module, Viscotek VE 3580 RI detector and 270 Dual Detector)
using 0.3 M acetic acid, 0.3 M sodium acetate, 0.02% sodium azide, 1% ethylene
glycol (pH 4.5) as the mobile phase.
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Acetylation of glycol chitosan with succinic anhydride (SA-GCS)
Succinic anhydride (SA) was grafted onto the above yielded low molecular
weight glycol chitosan (28 kDa) by acidification reaction. Briefly; glycol chitosan
(30 mg) was dissolved in deionized water (6 mL) and succinic anhydride (4.17
mg) was added under stirring. After 2 h of reaction at room temperature, the pH
of the reaction mixture was adjusted to 8 with NaOH (1 M). The reaction was
then allowed to proceed for another 2 h. The product was purified by dialysis
(Spectra 7 MWCO: 3500 Da) against water (pH 9) for one day and lyophilized for
48 h. The structural composition of modified glycol chitosan (SA-GCS) was
characterized by 1H-NMR spectroscopy. The appearance of methylene proton
peaks at δ = 2.4 to 2.6 ppm corresponding to succinic acid along with the glycol
chitosan peaks at δ = 2.06, 2.75, 3.7 and 4.5 ppm (Figure 1.3). To determine the
IEP of SA-GCS, ζ potential was measured as a function of pH using Zetasizer
Nano-ZS (Malvern, UK). In a typical experiment, 0.5 mg/mL polymer solution was
prepared in NaCl (10 mM), and the surface charges of SA-GCS at different pH
were recorded.
Modification of acetylated glycol chitosan (SA-GCS-SH)
To generate thiol groups on SA-GCS, SA-GCS was reacted with SPDP.
The introduced disulfide bonds were then cleaved by TCEP to yield free thiol
groups. Briefly; SA-GCS (60 mg) was first dissolved in dimethyl sulfoxide (10
mL). TEA (300 µL) and SPDP (21.63 mg) were then added under stirring. After
overnight reaction at room temperature, the disulfide bonds were cleaved by
adding TCEP thereby generating free thiol group. Then, the polymer was purified

13

by dialysis (Spectra 7 MWCO: 3,500 Da) against 10 mM EDTA (24 h) followed by
ddH2O (24 h). The product was obtained after lyophilization for 48 h and stored
at -20 °C. IEP of SA-GCS-SH was determined in a similar way as SA-GCS. The
concentration of thiol group was quantified by DTNB assay. The number of thiol
groups per polymer molecule was found to be 8.7 as calculated by DTNB assay.
Nano-complexes preparation and characterization
Melittin and SA-GCS-SH were dissolved in Tris buffer saline (TBS) pH 7.4
to get 0.1 mg/mL and 5 mg/mL, respectively. Then, 1 ml melittin solution was
incubated with different amounts (0.1 to 4 mL) of SA-GCS-SH solution for 1 h at
room temperature to get non-crosslinked complexes (single secured nano-sting,
SSNS). To develop cross-linked complexes (dual secured nano-sting, DSNS),
SSNS was aerially oxidized for 2 h at room temperature. SSNS and DSNS were
freeze-dried with 5% trehalose and stored at -20 °C until use. The binding
efficiency of SA-GCS-SH was measured by measuring the fluorescence of free
melittin. Free melittin from the complexes was separated by centrifugal filtration
at 14,000 rcf for 8 min using Nanosep 30 K Omega (Pall corporation, USA) and
the concentration was determined by measuring its fluorescence (λexi=280nm,
λemi=350 nm) using a SpectraMax M5 Multi-Mode Microplate Reader (Molecular
Devices). Nano-complexes prepared at the ratio of 200:1 (polymer: melittin, w/w)
were used for the following experiments.
The size and surface charge (ξ-potential) of the complexes were
measured using a Zetasizer Nano-ZS (Malvern, UK) at pH 7.4. The morphology
of the complexes was observed by transmission electron microscopy (Hitachi H-
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800 TEM) using a formvar/carbon coated Copper Grids (Electron Microscopy
Science). The original complexes solution (5 µL) was dropped on a grid, washed
with ddH2O (3 ×) to remove the remaining salt, and dried with a tissue paper.
HPLC determination of melittin was carried out with a Waters 2996 instrument
equipped with a photodiode array detector and a hypersil gold column (250 × 4.6
mm, Fisher); mobile phase: mixture of acetonitrile and water supplemented with
0.1 % TFA (linear gradient from 4:96 to 64:36, v/v, over 60 min); flow rate: 1.5
mL/min; detection: 220 nm. The retention time for melittin was 41.6 min.
Standard solutions were prepared by dissolving melittin in ddH2O followed by a
series of dilutions. Melittin stock solution was prepared at 100 μg/mL. For sample
preparation, 50 μg of SSNS and DSNS were dissolved in 500 μL ddH2O and the
free melittin solution was collected by centrifugation at 13,000 rcf for 30 min twice
with Nanosep centrifugal device 10K Omega (Paul life sciences). The resulting
filtrate (50 μL) was injected for HPLC determination. No peak detected at 41.6
min suggested that both SSNS and DSNS were free of free melittin (Figure 1.9).
FRET measurement
The donor fluorescence dye Cy3-NHS was chemically conjugated with
SA-GCS and SA-GCS-SH prior to forming the complex. Similarly, the receptor
fluorescence dye Sulfo-Cy5-NHS was conjugated with melittin. The conjugated
Cy3 amounts in SA-GCS and SA-GCS-SH were adjusted carefully to ensure that
the same conjugation efficiency was achieved, which was further validated by
measuring the fluorescence intensity of Cy3 with a SpectraMax M5 Multi-Mode
Microplate Reader. After that, SSNS was fabricated from Cy3-labeled SA-GCS
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and Cy5-labeled melittin, while DSNS was fabricated from Cy3-labeled SA-GCSSH and Cy5-labeled melittin. Cy3 and Cy5 dual-labeled SSNS and DSNS were
prepared following the same protocol except that the DSNS needed aerial
oxidation. Therefore, the amount of each dye in SSNS and DSNS was the same.
The titration of nano-complex was carried out by adding 0.1 M HCl and NaOH to
adjust pH to the pre-designed values. Both SSNS and DSNS samples were
loaded into Coring® 96 well black flat bottom plates. Samples were excited at
500 nm with the cutting off 530 nm. The entire fluorescence spectra (from 530
nm to 750 nm) of both nano-complexes were then recorded as a function of the
pH with the help of a SpectraMax M5 Multi-Mode Microplate Reader (Molecular
Devices).
Release kinetics of SSNS and DSNS
Cy5 labeled melittin were fabricated into SSNS and DSNS as described
above. SSNS and DSNS samples (2 mL) were loaded into dialysis bags (MWCO:
6000-8000). The dialysis bags were put into different media (pH 7.4,10 mM PBS
and pH 5, 10 mM acetic acid buffer) at 37 °C under continually stirring. At
predesigned time (1, 2, 4, 8 h), 1 mL sample was taken and supplemented with 1
mL corresponding fresh medium. Samples were lyophilized and re-suspend in
200 μL ddH2O. To calculate the release amount of melittin, the originally labeled
Cy5-melittn was employed to obtain standard curve with the help of a
fluorescence microplate reader. The fluorescence intensities of released samples
were quantified under excitation of 630 nm and emission of 670 nm.
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Hemolytic assay
Sprague Dawley Rat whole blood was purchased from Bioreclamation
LLC (NC, USA). Briefly, RBCs were washed with NaCl (210 mM) until no red
color was visible in the supernatant. The washed RBCs were used to compare
hemolytic effects of melittin, SSNS and DSNS using DI water as positive control
and PBS (pH 7.4) as negative control. Melittin of different concentrations (0.1 to 5
µM) and SSNS or DSNS (equivalent with free melittin) were added to fixed
number of washed RBCs (2.5×107 cells) and incubated at 37 ºC for 1 hour. The
release of hemoglobin was quantified by measuring the absorbance at 405 nm of
the supernatant in a microplate reader (ELX808, Bio-Tech Instrument) after
centrifugation at 300 rcf for 2 minutes. The results were expressed relative to the
reference standard. To investigate the effect of pH and redox potential on the
hemolytic activity of SSNS and DSNS, nano-complexes were co-incubated with
RBCs in PBS (pH 5.0) and PBS (pH 7.4) supplemented with 10 mM GSH,
respectively. The stability of DNSN was also tested by co-incubating RBCs with
DSNS in PBS buffer containing 50% serum.
Confocal microscopy
HCT-116 cells were seeded at a density of 2×104 cells per chamber slides
and allowed to grow for 24 h. SA-GCS and SA-GCS-SH were conjugated with
Cy3 followed by excessive dialysis to remove free Cy3. The purified Cy3 labeled
polymer were used to prepare SSNS and DSNS. After treated with SSNS and
DSNS for 2 h at 37 °C in a 5% CO2 incubator, cells were washed with PBS three
times and fixed with 4% formaldehyde in PBS, followed by staining with
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Hoechst33342 1 μg/mL (Invitrogen) and washed again with PBS for 3 times.
Finally, cells were imaged with confocal laser scanning microscopy (Zeiss LSM
700).
JC-1 Staining
HCT 116 cells were seeded in each petri dish at density of 300K cells per
dish. After overnight incubation, cells were treated with 2 μM Melittin or DSNS for
1 h. Cells were then stained with JC-1 for 30 min (Cayman chemical, MI), and
observed under confocal microscope using FITC and Texas Red channels.
Cytotoxicity assay
The anticancer activities of melittin and DSNS in MCF-7, HCT-116, SKOV3 and NCI/ADR-res cells were evaluated by MTT assay using melittin as a
positive control and non-treated cells as a negative control. The cells were
seeded in 96-well plates at an initial density of 12,000 cells/well in 150 μL of
DMEM medium supplemented with 100 U penicillin/streptomycin and 10% FBS.
After 24 h, the medium was replaced with 150 µL of fresh medium containing
DSNS and melittin (corresponding to 0.1 to 10 µM melittin) and incubated for
another 24 h. After the defined time of co-incubation, the media were replaced
with 100 µL fresh media containing 1 mg/mL MTT reagent and incubated for 4 h.
The formed MTT crystal was dissolved with a stop solution and the finally optical
density of the medium was measured using a microplate reader (ELX808, BioTech Instrument, Inc) at λ = 595 nm. The cytotoxicity of melittin and DSNS was
calculated as relative to the control group (untreated cell). The cytotoxicity of
oxidized SA-GCS-SH polymer was evaluated in parallel.
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SA-GCS-PDP

SA-GCS-SH

Figure 1.1 Schematic illustration of complex formation and reaction scheme of
the polymer synthesis. (A) Schematic illustration of the formation and intracellular
pathway of DSNS. (B) Reaction scheme for synthesis SA-GCS, SA-GCS-PDP,
and SA-GCS-SH.
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Figure 1.2 The GPC spectra of glycol chitosan and depolymerized glycol
chitosan.
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Figure 1.3 The 1H-NMR spectra in D2O of GCS, SA-GCS, SA-GCS-PDP, and
SA-GCS-SH. The circled area indicates the peaks of PDP.

21

Figure 1.4 IEP measurement of polymers. (A) The structure of SA-GCS-SH. (B)
The surface charges of SA-GCS and SA-GCS-SH at different pH.
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Figure 1.5 Binding efficiency characterization of nano-complexes. (A) Binding
efficiency of nano-complex formed at different polymer/melittin (w/w) ratios. (B)
Binding efficiency of SSNS and DSNS at different polymer/melittin (w/w) ratios.
Data represents mean ± SD, n=3.
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Figure 1.6 The size distribution of SSNS and DSNS determined by dynamic light
scattering.

24

Figure 1.7 Transmission electron microscopy images. (A) SSNS and (B) DSNS.
Scale bars are 100 nm.
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Figure 1.8 The surface charge of complex was determined by phase analysis
light scattering. (A) SSNS and (B) DSNS.
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Figure 1.9 HPLC spectra of SSNS and DSNS for the detection of free melittin in
the nano-complexes. (A) Solvent, (B) free melittin, (C) SSNS, and (D) DSNS.
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Figure 1.10 The FRET produced by DSNS. (A) The schematic of FRET
produced by DSNS and SSNS. (B) The measured FRET intensities of DSNS and
SSNS at different pH.
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Figure 1.11 The release kinetics of SSNS and DSNS at pH 7.4 and 5.0 buffers.
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Figure 1.12 Hemolytic assay after incubation of melittin, SSNS, and DSNS with
RBCs. (A) Images of RBCs after hemolytic assay. (B) The hemolytic activity of
melittin, SSNS, and DSNS.
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Figure 1.13 Hemolytic activity of melittin, SSNS, and DSNS at different pH
and redox potential conditions. * p< 0.05 and # p< 0.01 (unpaired Student’s
t-test).

31

Figure 1.14 The image of RBCs after co-incubating with DSNS in 50% serum
containing buffer.
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Figure 1.15 Uptake of SSNS and DSNS by confocal microscopy. Confocal
microscope images of HCT-116 colon cancer cells after incubation with SSNS
and DSNS for 2 h. Scale bars are 10 μm in all images (Blue-Hoechst, Red-Cy3
labeled SSNS or DSNS).
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Figure 1.16 Cytotoxicity evaluation of DSNS. The light microscopy images of the
morphologies of NCI/ADR-RES cells treated with 5 µM melittin. (A) Control, (B)
free melittin, (C) DSNS. (D-G) Cytotoxicity of DSNS and melittin treatments in
different cancer cell lines. (D) HCT-116, (E) MCF-7, (F) SKOV-3, (G) NCIADR/RES.
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Figure 1.17 Mitochondrial membrane potential changed with the incubation with
melittin and DSNS. Confocal microscope images of HCT-116 colon cancer cells
after incubation with melittin and DSNS for 1 h and stained with JC-1. Scale bars
are 10 μm in all images. Green fluorescence indicates depolarized membrane
potentials (JC-1 monomer form) due to the damaged mitochondria function, and
red indicates hyperpolarized membrane potentials (JC-1 aggregation).
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Figure 1.18 Cytotoxicity of SA-GCS-SH. Polymers at the corresponding melittin
concentration of 0.1 to 10 μM were tested in SKOV-3, MCF-7, NCI/ADR-RES,
and HCT-116 cancer cells.
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CHAPTER 2
Gold nanosphere gated mesoporous silica nanoparticle responsive to
NIR light and redox potential as a theranostic platform for cancer
therapy 2
ABSTRACT
A gold/mesoporous silica hybrid nanoparticle (GoMe), which possesses
the best of both conventional gold nanoparticles and mesoporous silica
nanoparticles, such as excellent photothermal converting ability as well as high
drug loading capacity and triggerable drug release, has been developed. In
contrast to gold nanorod and other heat generating gold nanoparticles, GoMe is
photothermal stable and can be repetitively activated through NIR irradiation.
Doxorubicin loaded GoMe (DOX@GoMe) is sensitive to both NIR irradiation and
intracellularly elevated redox potential. DOX@GoMe coupled with NIR irradiation
exhibits a synergistic effect of photothermal therapy and chemotherapy in killing
cancer cells. Furthermore, 64Cu-labeled GoMe can successfully detect the
existence of clinically relevant spontaneous lung tumors in a urethane-induced
lung cancer mouse model through PET imaging. Altogether, GoMe can be
utilized as an effective theranostic platform for cancer therapy
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37

INTRODUCTION
Gold nanoparticles, including gold nanosphere (GNS), gold nanorod
(GNR), gold nanoshell (GNSH), and gold nanocage (GNC), have attracted
tremendous attentions during the past decade and have been extensively
explored in biomedical applications, such as drug and gene delivery, disease
detection, treatment, and response monitoring, due to their excellent
biocompatibility, and easy surface modification.33 Upon irradiation, gold
nanoparticles generate heat attributable to the localized surface plasmon
resonance (LSPR) phenomenon.34 By manipulating their shape, size, and
geometry, the LSPR peak of GNR, GNSH, and GNC can be tuned to nearinfrared (NIR) region, also called tissue transparent window (650-900 nm), within
which light can penetrate deeply.35 Because of that, upon NIR irradiation, these
gold nanoparticles generate heat and can be applied for photothermal
therapy.34a, 36 Although gold nanoparticles have been evaluated in numerous
systems and proven to be promising in photothermal therapy and drug delivery,
there are several intrinsic properties limiting their translation from bench to
clinical practice. First, due to their poor photothermal stability, traditional gold
nanoparticles gradually lose their photothermal converting capacity upon
repetitive NIR irradiation. It has been well documented that the shape and
extinction of GNR changed after NIR laser irradiation and resulted in lower heat
generating capacity after each heating/cooling cycle.37 Similar scenarios also
have been observed in GNSH and GNC if the generated heat could not be
dissipated to their surrounding environment.38 In addition, except GNCs, other
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gold nanoparticles are not good drug carriers either due to limited drug loading
capacity or poorly controlled drug release profile.39 Furthermore, although
tremendous efforts have been devoted, how to effectively integrate both
photothermal therapy and chemotherapy modules into one system remains a
challenge, especially when repetitive activation is needed.
Similar as gold nanoparticles, last decade also witnessed increasing
attention gained by mesoporous silica nanoparticle (MSN) due to its high and
versatile drug loading capacity as well as good biocompatibility. Numerous MSN
based carrier systems have been developed for the delivery of drugs, peptides,
DNAs, and siRNAs. To better control the release kinetics of their payloads, many
gatekeepers have been explored, such as polyelectrolytes,40 macrocyclic organic
molecules,41 and inorganic nanoparticles.42 Generally, these MSN delivery
systems are responsive only to the changes in the physiological environment,
such as pH and redox potential. Once the MSN is administrated in vivo, the drug
release profile will be out of the control of the clinician and be totally relying on its
fabrication method and biodistribution. To overcome the limitations of existing
gold nanoparticles and MSNs in photothermal therapy and drug delivery, we
developed a gold/mesoporous silica hybrid nanoparticle (GoMe) by conjugating
gold nanospheres (GNS) onto the surface of MSN (Figure 2.1A) to take
advantage of the best of both worlds.
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RESULTS
Gold/mesoporous silica hybrid nanoparticle (GoMe) fabrication
Thiolated MSN was fabricated by the co-condensation of (3-mercaptopropyl)
trimethoxysilane (MPTMS) with tetraethyl orthosilicate (TEOS). With CTAB and
F127 applied as structure directing agents, these silica sources were able to be
constantly hydrolyzed. After the nanoparticle grew to a certain size, the template
of CTAB was removed by ion exchange with ammonia nitrate. TEM revealed that
most MSNs are in spherical or oval shape with a size of 50.87 ± 10.69 nm
(Figure 2.1B). The N2 sorption measurement revealed that the pore size of MSN
is about 2-3 nm (Figure 2.2), with a surface area of 858 m2/g. The accessible
thiol groups on the MSN were quantified with Ellman’s reagent using cysteine as
a reference standard. The amount of thiol groups in MSNs was 31 μmol/g. The
super stable gold nanosphere (GNS) was synthesized according to literature with
minor modification.43 Thiolated polyethylene glycol (PEG-SH, Mw=2000 Da) was
added into the gold isopropanol alcohol solution before the formation of GNS.
The resulting PEG-GNS was spherical with a diameter of 3.93 ± 0.70 nm (Figure
2.1C). The resulting PEG-GNS was further functionalized through a two-step
procedure by conjugating PEG-GNS with cysteamine first, followed by reacting
with homemade 2-(pyridin-2-yldisulfanyl)ethyl acrylate (PDA) via Michael addition
reaction to yield PDA-GNS as shown in Figure 2.1A. DTNB assay revealed that
about 200 PDA molecules were anchored to each GNS. PDA-GNS was grafted
onto MSN through thiol-disulfide exchange reaction (Figure 2.1A) by simply
mixing PDA-GNS and thiolated MSN in DI water for 24 h. TEM was employed to
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investigate the assembly between GNSs and MSNs. Figure 2.1C showed that
most GNSs were evenly attached to the surface of MSNs. This gold
nanosphere/mesoporous silica nanoparticle hybrid assembly was named as
GoMe. To our surprise, only a few free GNSs were detected after the reaction,
indicating the high efficiency of the conjugation reaction. The success of grafting
of GNS onto MSN was further confirmed by SEM image and SEM/EDX analysis.
The evenly distributed small spherical dots on the bigger balls (Figure 2.3) and
the presence of gold element (Figure 2.4 and 2.5) indicated that GoMe had a
structure as shown in Figure 2.1A. Zetasizer found that GoMe carried slightly
negative surface charge (-5.92 ± 0.75 mV, Figure 2.6). Due to the existence of
PEG outer layer, GoMe was stable in culture medium containing 10% FBS
(Figure 2.7), and no obvious size change and aggregation were observed after
two months of incubation. The size of GoMe determined by dynamic light
scattering (DLS, 141.7 nm) was larger than that observed by TEM (54.71 ± 9.63
nm), which is because that TEM measures physical size of the dried particles
while DLS measures their hydrodynamic diameter (including the water layer
surrounding the particle).
Photothermal property characterization
To monitor the fabrication progress of GoMe, UV-Vis spectrophotometer
was employed by recording the absorbance from 400 to 1000 nm during the
reaction. Figure 2.8A showed that the absorbance peak of the reaction mixture
at 524 nm decreased over time and slightly shifted to long wavelength direction,
while its absorbance in the NIR region gradually increased. To evaluate the
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photothermal properties of the reaction mixture changing with the progress of the
reaction, the reaction suspension was irradiated with NIR laser (808 nm, 2.83
W/cm2) for 10 min at predesigned time intervals and its temperature was
monitored with a FLIR i7 thermal imaging camera and recorded every 30 sec.
Before the mixing, the aqueous nano-suspension of MSN produced none while
GNS produced little heat under the NIR irradiation (Figure 2.8B). To our
surprise, after 12 h of reaction, the temperature of the mixture of MSN and GNS
raised 21.2 °C after irradiation (Figure 2.8B). Furthermore, the longer the
reaction time, the higher the temperature reached. The mixture after 24 h of
reaction could be heated to 52.8 °C (30 °C increase) upon the same intensity and
length of NIR irradiation. The photothermal conversion efficiency of GoMe was
29.65%, which is slightly higher than the reported GNSH (25%) while lower than
GNR (50%).44
To probe the mechanism for the mixture of GNS and MSN generating heat
upon NIR laser irradiation, TEM was employed to observe the morphology
change during the reaction. The reaction mixture was centrifuged to remove
unconjugated GNS before loaded onto copper grids for TEM observation. Figure
2.8C showed that GNSs can be conjugated onto MSN within 2 h. Longer reaction
time resulted in a higher GNS decorating density on the surface of MSN (Figure
2.8D and 2.8E). Altogether, higher decorating density of GNS on GoMe led to a
higher absorbance in the NIR region, which opened the window for the
biomedical application of GoMe using a NIR laser (Figure 2.8A). As a
consequence, GoMe with higher GNS decorating density produced more heat
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upon the NIR laser irradiation (Figure 2.8B). Figure 2.9 revealed that GoMe
exhibited a concentration-dependent photothermal heating effect. Therefore, a
desired photothermal heating curve can be achieved by simply tuning the
concentration of GoMe. Photothermal stability is a vital property for the success
of photothermal therapy, especially when repetitive treatment is necessary for the
management of recurrent cancer. To evaluate the photothermal stability of
GoMe, aqueous suspension of GoMe was repetitively irradiated with the 808 nm
NIR laser (10 min on and 20 min off) at the light intensity of 2.83 W/cm2. The
temperature of the nano-suspension was monitored as described above. GNR
(aspect ratio of 3.89 and peak absorbance of 804 nm) synthesized according to
literature was employed as a control.45 GNR at a concentration that could
produce heat to reach similar temperature as that of GoMe was irradiated in
parallel. Figure 2.10 showed that the temperature of both GoMe and GNR
suspensions increased rapidly upon laser irradiation and reached 74 °C in 10
min. As expected, the repetitive heating of GNR suspension resulted in
decreased peak temperatures, declined from 74 to 65.8 °C during the second
heating cycle and further dropped to 48.5 °C after 6 cycles of laser irradiation
induced heating/cooling. In an apparent advancement to the field, GoMe
suspension could reach the same peak temperature after 6 heating/cooling
cycles, and achieved even higher peak temperature after 24 h of resting period,
which suggests that GoMe was stable in keeping its photothermal property
during laser irradiation induced heating/cooling process. Such stability is critical
for certain biomedical applications which require multiple laser irradiations. Since
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GNSs were grafted onto MSN through disulfide bonds, the photothermal property
of GoMe in reducing environment was further investigated. Figure 2.11 showed
that GoMe only slightly decreased its peak temperature in an environment
containing 10 mM GSH, suggesting that most of GNSs were still attached to
MSN. As we have confirmed that each GNS had 200 thiol reactive PDA groups, it
is reasonable to postulate that every GNS was connected with MSN through
multiple disulfide bonds. Therefore, at any given time, GSH only cleaved partial
of those disulfide bonds for each GNS and loosened the binding between GNS
and MSN. More importantly, repetitive heating/cooling in reducing environment
did not change its photothermal converting capacity (Figure 2.11). Therefore,
GoMe would retain its competence in generating heat upon NIR irradiation in an
intracellular environment, where it has high GSH level.46
To probe why GoMe was stable during the NIR laser irradiation induced
heating/cooling cycles, while GNR was instable, the UV-Vis spectra of GoMe and
GNR after each cycle were recorded. The UV-Vis absorbance of GoMe only
marginally changed after 6 cycles of heating/cooling (Figure 2.12A), while the
absorbance of GNR significantly diminished in the NIR region (Figure 2.12B). To
investigate the morphologies of the GNR and GoMe after above treatment, TEM
was employed. Figure 2.12D proved that the morphology of GoMe remained
intact after laser irradiation. By contrast, some GNRs changed their shape
significantly after 5 cycles of laser irradiation, becoming shorter and fatter or
round (Figure 2.12F). This rod-to-sphere shape transformation was due to the
melting of GNR under the extensive heat itself generated.47 Since gold
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nanoparticles melt at high temperature and form gold nano-droplet (or so called
nanosphere), similar shape transformations also have be documented for gold
nanoshells and gold nanocages.38c As a consequence of losing their original
geometries, these gold nanoparticles showed a compromised photothermal
property. However, GoMe, which was fabricated from GNS and MSN, kept its
shape unchanged, since GNS remained its original spherical after melting.
Therefore, GoMe kept its photothermal capacity intact over multiple
heating/cooling cycles.
Drug release kinetics measurement
To investigate whether the decoration of GNS on the surface of MSN
could affect the release profile of its payload, anticancer drug doxorubicin (DOX)
was adopted as a model drug and loaded into MSN as described by literature.33
Due to its high surface area and pore volume, GoMe achieved 28% drug loaded
content. Because DOX is a potent anticancer drug, DOX loaded GoMe
(DOX@GoMe) of 4.58% drug loading content was adopted for the in vitro assay.
However, in drug release kinetics study, the DOX@GoMe of 28% drug loading
content was employed to achieve a more accurate drug release profile.
An ideal drug carrier should be premature-release free before reaching its
target. Furthermore, for a desired delivery system, the release of its payload
should be either spontaneously responsive to the stimuli from its target or
remotely controlled by external signals. To investigate the release kinetics of
DOX from GoMe, DOX@GoMe was suspended in phosphate buffer (PBS, pH
7.4) and PBS supplemented with 10 mM GSH to mimic the environments in the
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circulating blood and cytosol, respectively. Researchers found that surface nonmodified MSN can easily aggregate in aqueous medium,48 which could result in
false release profile. For fair comparison, DOX loaded MSN (DOX@MSN) was
also stabilized though PEG-SH surface modification. Figure 2.5A showed that
DOX@MSN released more than 28.8% of its payload within 10 h of incubation in
PBS, suggesting that unsealed MSN was not a desired carrier. Interestingly,
GoMe, MSN decorated with GNS, released much less of DOX (8.3%) within the
same period of time, indicating that GNS could serve as a plug to prevent DOX
from leaking out from the pores of MSN during circulating in blood stream. Since
GNS was conjugated onto the surface of MSN through disulfide bonds, we
further investigated the responsiveness of GoMe to reducing environment by
dispersing it in PBS supplemented with 10 mM GSH. As expected, GoMe
released much more DOX in reducing environment (66.4% of DOX within 24 h)
than that in PBS (10.3%), demonstrating that GoMe was a good carrier for
intracellular drug delivery. As we already proved that GoMe could efficiently
convert NIR laser irradiation into heat, we further investigated the effect of NIR
irradiation on drug release by applying irradiation (10 min laser on in every 24 h
period) on the GoMe nano-suspension. Remarkably, Figure 2.13B showed that
10 min of NIR irradiation induced more than 23% immediate DOX release. The
removal of laser irradiation promptly slowed down the drug release. Moreover,
the re-introducing of laser irradiation could accelerate drug release repetitively.
The first time NIR irradiation triggered more drug release than the later ones,
which possibly due to the liberation of drugs bonded on the surface MSN for the

46

first irradiation while later stimuli induced the release of encapsulated drugs from
the pores of MSN. This light activable two-stage drug release pattern can be
utilized to meet the clinical setting in drug administration by providing both
loading dose and maintenance dose.
Observation of GoMe by confocal fluorescent and dark-field microscopies
To explore the potential of using GoMe as a carrier to deliver drug into
cancer cells, DOX-loaded GoMe was co-incubated with A2058 melanoma cells
for 3 h, and then observed with a confocal microscope. The red fluorescence
signals in Figure 2.14F proved that GoMe loaded DOX could effectively enter
A2058 cells. To further confirm that GoMe entered cancer cells, the above cells
were also observed with a dark-field microscope. Scatter light signals (yellow and
red dots) collected inside A2058 cells (Figure 2.14J) through a dark-field
detector proved that GoMe could be taken up by cancer cells.
Cell killing effect of GoMe
Figure 2.15 displayed that GoMe raised medium temperature from 21.8 to
34.6 and 50.3 °C within 10 min of laser irradiation at GoMe concentrations
corresponding to 1.67 and 5 μM DOX, respectively. Since GoMe could generate
heat and raise medium temperature upon NIR laser irradiation, we first
investigated its photothermal therapy effect on the cancer cells through
Live/Dead cell assay. A 2058 cells were co-incubated with blank GoMe at the
corresponding Dox concentration of 5 μM and coupled with NIR laser irradiated
for 10 min before the Live/Dead cell assay, and then visualized with a fluorescent
microscope. As expected, nearly all non-treated cells were stretched and green
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(Figure 2.16A). It was also noted that blank GoMe treated cells (Figure 2.16B)
did not show any morphology difference as compared with the non-treated ones,
suggesting GoMe itself was not toxic. By contrast, cells treated with blank GoMe
and laser irradiation dramatically changed their morphology, showing round
shape (Figure 2.16C). It was also noticed that the cell density in Figure 2.6C was
much lower than the group without receiving laser irradiation, which was due to
the detaching of cells as a result of apoptosis and subsequently being removed
during the washing procedure. In addition, a significant portion of cells in Figure
2.16C were stained in red, confirming that GoMe coupled with NIR irradiation
could effectively kill cancer cells.
We have confirmed that NIR laser irradiation could trigger the release of
DOX from GoMe, and also proved that photothermal effect of blank GoMe could
kill cancer cells. To investigate the cell killing efficacy of DOX@GoMe coupled
with NIR irradiation, A 2058 cells receiving different treatments were analyzed by
MTT assay. Due to the potential residual of cetyl trimethylammonium bromide
(CTAB) in the MSN, blank GoMe showed some cytotoxicity. As expected, the
application of NIR irradiation enhanced the cell killing effect of GoMe (Figure
2.16D), especially for GoMe at the concentration of 5 μM. Because the capping
effect of GNS and consequent slower drug release, DOX@GoMe was less
potent than DOX@MSN in killing cancer cells. Furthermore, Figure 2.16D also
evidenced that the DOX@GoMe coupled with NIR irradiation did show superior
anticancer efficacy than either GoMe coupled with NIR irradiation or
DOX@GoMe alone. Due to the photothermal effect of GoMe, NIR irradiation of
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DOX@GoMe could kill cancer cells by the combination effect of photothermal
ablation and boosted drug release and subsequent enhanced chemotherapy. It is
worth noting that the effect of NIR irradiation only became significant when GoMe
concentration reached 2 μM, at which GoMe could generate enough heat to
ablate cancer cells and augment drug release. The combination index (CI)
analysis further revealed that the combination of DOX@GoMe and NIR
irradiation exhibited synergistic effect at the DOX concentration 5 μM (CI value =
0.50).49 Therefore, to warrant the synergistic effect between DOX@GoMe and
NIR irradiation, high retention of DOX@GoMe in the targeted tissue or cells is
required.
In vivo tumor detection
To endow the PET imaging function to GoMe, DOTA was conjugated onto
GoMe nanoparticles by adding maleimido-mono-amide-DOTA. With the help of
conjugated DOTA, the yield for GoMe 64Cu-labeling was above 98%, which
suggests that GoMe is a good carrier for radiopharmaceuticals. To validate that
64

Cu-labeled GoMe can be used as a tool for cancer detection, a clinically

relevant spontaneous lung tumor model was employed. The 3 small tumors in
the lung (previously revealed by a ClinScan MRI system as shown in Figure
2.17A) were clearly detected by PET at both 6 h (Figure 2.17B and C) and 20 h
(Figure 2.17D) post-administration, suggesting the high retention of GoMe in the
tumor, which proved that GoMe is good tool for the cancer detection. Similar as
other nanoparticles, significant amount of GoMe nanoparticles accumulated in
liver and spleen as shown in the PET images. The increase of PET signals in the
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abdomen (colon and rectum) from 6 h to 20 h revealed the rout for GoMe to be
cleared from the body.
DISCUSSION
Various gold/silica hybrid nanoparticles have been explored as tools for
bioimaging and drug carrier. Lee et al. revealed that α-synuclein-coated gold
nanoparticle decorated MSN could release its payloads upon the intracellular
Ca2+ stimulus.50 Aznar et al. developed a gold/MSN hybrid system through the
formation of boronate esters. Due to the hydrolysis of boroester bonds at acidic
pH and light induced heat, low pH and light can be used to trigger the release of
its cargo.42a In addition, Sharma et al. also found that gold nanoparticle coated
silica nanoparticles could produce strong signals for magnetic resonance imaging
(MRI) and photoacoustic tomography (PAT).51 In our design, gold nanospheres
were grafted onto the surface of MSN through disulfide bonds, which endowed
the intracellular redox potential responsiveness to GoMe. The surface-assembled
GNS can be considered as a structure well-defined assembly of “chainlike gold
nanoparticles”,52 or a discontinuous form of gold nanoshell, both of them can
efficiently generate heat upon NIR irradiation. In contrast to its continuous
counterpart, GoMe kept its original shape after NIR irradiation due to the distance
between each GNS and the support of MSN. Consequently, GoMe exhibited
stable photothermal property. Because the release kinetics of GoMe is super
sensitive to the NIR irradiation, DOX@GoMe showed synergistic effect in killing
cancer cell upon NIR irradiation. Since the first in vitro report of mesoporous
silica-coated gold nanorod reported by Zhang et al.,53 several recent studies
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explored its application for tumor growth inhibition in vivo.54 However, none of
them have been utilized for cancer detection. Due to the abundance of PDA
segments on the GNS, GoMe could be conveniently modified with DOTA and
achieved excellent chelating capacity needed for PET imaging. To the best of our
knowledge, GoMe is the first gold/mesoporous silica hybrid nano-system which is
capable of both detecting clinically relevant spontaneous tumor and achieving the
synergetic effect of photothermal therapy and chemotherapy in killing cancer
cells. To further enhance the sensitivity of its cancer detection capacity and boost
its anticancer efficacy, the next step research will incorporate tumor targeting
ligands, such as RGD peptide, folic acid, and anisamide, which target cancer
cells overexpressed integrin,55 folate,55b, 56 and sigma-2 receptors,32b, 57
respectively, into GoMe. In summary, a photothermal stable gold/mesoporous
silica hybrid nanoparticle (GoMe), which possesses the merits of both
conventional gold nanoparticles and mesoporous silica nanoparticles, such as
good photothermal converting ability and high drug loading capacity, has been
developed. In contrast to other MSN based system, GoMe is well dispersed in
serum containing medium. Contrary to GNR and other heat generating gold
nanoparticles, GoMe is stable in structure and maintains its photothermal
converting capacity after repetitive NIR irradiation. The release of drug from
GoMe can be triggered by both intracellularly elevated redox potential and NIR
irradiation. The localization of doxorubicin loaded GoMe can be detected by both
fluorescence and dark-field microscopies. In addition, the combination of
DOX@GoMe and NIR irradiation exhibited synergistic effect at the DOX
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concentration 5 μM through the integration of photothermal therapy and
chemotherapy. Furthermore, PET imaging proved that GoMe is a good tool for
the detection of clinically relevant spontaneous lung tumor. Based on these
promising in vitro and in vivo results, further studies will focus on the
pharmacokinetics of GoMe and utilizing it as an effective tool for image-guided
cancer therapy.
MATERIALS AND METHODS
Materials
Terraethylorthosilicate (TEOS), (3-mercaptopropyl)trimethoxysilan)
(MPTMS), hexadecyltrimethyl ammonium bromide (CTAB), sodium hydroxide
(NaOH), pluronic® F-127, ammonium nitrate, methanol, gold chloride trihydrate,
cysteamine hydrochloride, 2,2’-dipyridyl disulfide, triethylamine (TEA),
doxorubicin (DOX), and sodium borohydride (NaBH4) were purchased from
Sigma-Aldrich. PEG2000-SH was purchased from Laysan Bio. Ethanol and
acetic acid were acquired from Fisher Scientific.
Synthesis of mesoporous silica nanoparticles (MSN)
The MSN was synthesized in a dual surfactant system using a classic fast
self-assembling method containing both the cationic surfactant cetyl
trimethylammonium bromide (CTAB) and non-ionic surfactant triblock polymer F
127 to obtain a good suspending nano-sized MSN. In a typical synthesis, CTAB
(50 mg) and F 127 (40 mg) were dissolved in 24 mL DI water. After that, NaOH
aqueous solution (175 μL, 2M) was added into the above mixture. The reactants
were heated to 80 °C with vigorous stirring for 30 min. TEOS (200 μL) was added
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dropwise to the above solution followed by 3-mercaptopropyl trimethoxysilan
(MPTMS, 20 μL). A white precipitant was formed after a few minutes and the
mixtures were allowed to stir for 2 h at 80 °C. The crude product was collected by
centrifugation at 16,000 rcf for 15 min. CTAB was removed through ion exchange
by washing in ethanol solution of NH4NO3 at 50 °C. This process was repeated
for 3 times, followed by extensively washing with ethanol and the purified product
was stored at 4 °C in ethanol solution.
Synthesis of PEG stabilized gold nanosphere (PEG-GNS)
The super-stable gold nanosphere was synthesized according to literature
with minor modification.43 Briefly, gold (III) chloride trihydrate (12 mg) was first
dissolved in 18 mL isopropyl alcohol and followed with the addition of 0.2 mL
acetic acid. Thiolated polyethylene glycol (PEG-SH, MW=2000 Da) (15.24 mg in
2 mL isopropyl alcohol) was added into the gold alcohol solution. The mixture
was stirred for 1 h at room temperature following the addition of sodium
borohydride (37.84 mg in 1.5 mL methanol). The reaction mixture was stirred
vigorously overnight at room temperature. After overnight reaction, the mixture
was centrifuged for 30 min (2500 rcf) to remove large particles. The resulting
supernatant was precipitated in hexane. The precipitant was re-dispersed in 5
mL DI water. To remove free PEG-SH from gold nanoparticle, the PEG-GNS was
purified by repeatedly washing with water in a Millipore Centricon (MW
CO=10,000 Da). The successful anchoring of PEG-SH onto gold nanosphere
was confirmed by 1H-NMR (Figure 2.18A). The zeta potential of PEG-GNS was
measured by Zetasizer Nano ZS (Malvern) and showed a near neutral potential
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(-8.65 mV), which further confirmed the successful coating of PEG onto the GNS.
The morphology of PEG-GNS was confirmed by TEM. The UV-Vis spectrum of
PEG-GNS was recorded by UV-Vis spectrophotometer (DU®650
Spectrophotometer, Beckman Coulter, USA), which showed an absorbance peak
at 510 nm.
Synthesis of 2-(pyridin-2-yldisulfanyl)ethyl acrylate modified GNS (PDAGNS)
PDA-GNS was synthesized in a two-step procedure by conjugating PEGGNS with cysteamine first, followed by reacting with 2-(pyridin-2-yldisulfanyl)ethyl
acrylate (PDA) through Michael addition reaction. Briefly, the PEG-GNS
synthesized above was dispersed in 10 mL DI water, and then cysteamine (0.216
mg in 40 µL H2O) was added. The mixture was kept stirring at room temperature.
After 24 h of stirring, the reaction solution was loaded to a Millipore Centricon
(MWCO=10,000 Da) and repeatedly washed by centrifugation to remove unreacted cysteamine. The successful conjugating of cysteamine was confirmed by
zeta potential measurement, which showed a highly positive charge (+27 mV) on
the GNS surface. The surface amine concentration was further measured by
TNBSA assay, which also proved the successful replacement of PEG by
cysteamine. The GNS concentration was determined by calculating UV-Vis
absorbance. The result showed that there were around 1000 –NH2 groups
located on the surface of each GNS. After that, PDA was conjugated to the GNS
by reacting with amine groups via Michael addition reaction. Typically,
cysteamine modified GNS was dispersed in 500 µL of DMSO, and triethylamine
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(0.265 µL in 26.5 µL DMSO) was added, following the addition of PDA (0.459 mg
in 50 µL DMSO). The ratio between –NH2 and PDA was optimized at 2:1 since a
higher -NH2 to PDA ratio could easily result in GNS aggregation during the postpurification process. The reaction mixture was purged with nitrogen and then
kept at 50 °C for 24 h. The resulting PDA-GNS was precipitated in cold ether for
three times to remove unreacted PDA and finally re-dispersed in 2 mL DI water.
The successful conjugation of PDA was confirmed by UV-Vis spectrum (Figure
2.18B). PDA-GNS showed a PDA characteristic peak around 375 nm after
reacting with dithiothreitol (DTT). The PDA concentration of PDA-GNS was
measured by DTNB assay, which proved that about 200 PDA was anchored to
each GNS.
Encapsulation of doxorubicin (DOX) into MSN
To load DOX into MSN, DOX•HCl was firstly converted to its base form by
mixing with triethylamine for 30 min. In a typical synthesis batch, 10 mg DOX was
added to 18.6 mg MSN and the mixture was sonicated for 30 min to obtain a
uniform dispersion. The mixture was stirred at room temperature for 24 h and the
unloaded DOX was removed by washing with DI water twice. It was denoted as
DOX@MSN. The loading efficiency of DOX was quantified by a
fluorospectrometer (Beckman Coulter, DTX 880). Different loading of DOX can
be simply tuned by changing the ratio between DOX and MSN. In this
experiment, the highest drug loading content of DOX in DOX@MSN reached
28%.
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Fabrication of GNS decorated MSN (GoMe)
GNS was grafted onto MSN through thiol-disulfide exchange reaction.
MSN (200 μg in 200 μL) aqueous solution was added to 2 mL PDA-GNS
aqueous suspension while stirring. The mixture was allowed to react at room
temperature for 24 h, and then washed three times with DI water (Figure 2.1).
The final product was collected by centrifugation. The size and morphology of the
GoMe was determined by TEM. Cells were plated onto 12-mm glass coverslips
in 24-well plates prior to drug treatment or transfection.
Photothermal stability assay
The repetitive laser irradiation experiments were carried out to test the
photothermal stability of GoMe and gold-nanorod, which is critical for multiple
photothermal treatments. Firstly, the concentration of GoMe and gold nanorod
were adjusted to generate equal increment in temperature upon the same
intensity of laser irradiation. The GoMe suspension was irradiated by the 808 nm
laser for 10 min (Scorpius D-700 laser, 2.83 W/cm2). The temperature of the
nano-suspension was monitored with a FLIR i7 thermal imaging camera and
recorded every 30 sec. Both the GoMe and the GNR (maximum absorbance
peak at 804 nm) were undergone 6 continuous laser irradiation cycles (10 min
irradiation and 20 min cooling). The 7th irradiation was applied 24 h after the 6th
cycle. The UV-vis spectra and TEM images were recorded to reveal the change
during the repeating cycles. The photothermal stability of GoMe in reducing
environment was further investigated by dispersing GoMe in DI water
supplemented with 10 mM GSH.
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Laser irradiation triggered release of GoMe
To evaluate the responsiveness of GoMe to NIR light, 20 μL of GoMe
containing 4 μg of DOX was diluted with 250 μL DI water. The GoMe suspension
was incubated at 37 °C to carry out the release study. GoMe nano-suspension
was centrifuged at 1, 2, 4, 6, 8, 12, and 24 h at 16,000 rcf for 10 min to separate
released DOX from GoMe particles. After that, the same amount of fresh medium
was added to re-suspend the GoMe pellet. At 24 h post the start of the releasing
experiment, the GoMe suspension was irradiated by an 808 nm laser for 10 min
(2.83 W/cm2). Sample was collected immediately by centrifugation after the
irradiation. The sample was then incubated at 37 °C followed by sampling twice
(at 1 h intervals), and then incubated till the next 24 h point. The whole release
process was continued for 4 days. The amount of DOX in the supernatant was
determined by a fluorospectrometer (Beckman Coulter DTX 880, excitation: 485
nm and emission: 545 nm).
GNS decorating density effect assay
The effects of different GNS density on a single MSN were explored by
examining the product of the reaction between GNS and MSN at different time
intervals. The reaction was carried out in a transparent 2.5 mL
spectrophotometer cuvette. The UV absorbance spectrum was recorded directly
as the reaction proceeding, while the photothermal converting capacity of the
mixture was examined by irradiating the diluted reaction mixture with the 808 nm
laser. The reaction was also monitored by observing the morphology of GoMe
with the help of TEM.
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Cellular internalization assay
The A 2058 cell, a human melanoma cell line, was cultured in Dulbecco’s
modification of eagle medium (Corning, Manassas, VA) supplemented with 10%
FBS and 1% penicillin-streptomycin (Life Technology, Grand Island, NY) at 37 °C
in 5% humidified CO2 atmosphere. Cells were seeded in 35 mm petri dishes with
a density of 200,000 cells/petri dish. After overnight incubation, 5 μM
DOX@GoMe was added and continued incubation for another 3 h. Cells were
washed once with complete medium and then stained with Hoechst 33342,
followed by confocal microscopy imaging (LSM 700, Zeiss) and dark field
microscopy imaging (Leica DM6000 M).
Live/dead cell assay after photothermal therapy
The photothermal effect of GoMe in cell culture medium was evaluated in
a 96-well plate. GoMe of different concentrations were added to each well
containing 100 μL complete medium. The resulting GoMe nano-suspension was
irradiated with NIR laser (808 nm, 2.83 W/cm2) for 10 min at predesigned time
intervals and its temperature was monitored with a FLIR i7 thermal imaging
camera and recorded every 1 min. To visualize the effect of laser irradiation on
the cell death, Live/Dead cell imaging kit (Molecular Probe®) was used. 10,000
cells were seeded in 96-well plate and incubated at 37 °C in 5% CO2 overnight.
Blank GoMe (1 μM or 5 μM) was added and incubated for 2 h. For GoMe treated
groups, an 808 nm laser was used to irradiate cells for 10 min, while others had
no laser treatment. Cells were kept in the incubator for 2 h and stained with
Live/Dead cell imaging kit according to the manufacturer's instruction. Each well
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was imaged from 5 different positions (top, bottom, left, right and middle) with
fluorescent microscopy (Axiovert 200, Carl Zeiss) under 20 × magnification using
FITC and Texas red channels.
Cytotoxicity assay
For cell viability assays, A2058 cells were seeded in a 96-well plate
(10,000 cells/well) and incubated at 37 °C in 5% CO2 overnight. DOX, MSN,
DOX@MSN, GoMe, and DOX@GoMe were diluted with complete medium to
achieve targeted concentrations. After 24 h of incubation, GoMe and
DOX@GoMe irradiation groups were exposed to 808 nm laser irradiation for 10
min. The cells were allowed to grow overnight and then added with MTT reagent.
MTT stop solution was added after 4 h of incubation to dissolve MTT formazan
crystals. The optical density of the medium was measured using a microplate
reader (ELX808, Bio-Tech Instrument, Inc.) at λ = 595 nm.
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Cu Radiolabeling of GoMe Nanoparticle
DOTA was conjugated onto GoMe nanoparticles by adding Maleimide-

mono-amide-DOTA (20 mM, 50 μL in DMSO) to 1 mg GoMe aqueous solution (1
mg/ml). After 6 h of reaction at room temperature, the free DOTA was separated
from GoMe by centrifugation and washing with DI water twice. The resulting
pellet was re-suspended in 1 ml DI water. GoMe nanoparticles were further
radiolabeled by 64Cu via the DOTA chelator as previously reported 58. The
radiolabeling was accomplished by addition of 1.0-1.5 mCi of 64CuCl2 in 0.1 M
HCl (University of Wisconsin) to a mixture of 50 μL 0.1 N ammonium acetate (pH
5.5) buffer and 150-200 μL of the nanoparticles suspension, followed by
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incubation at 37 °C for 30 min. The radiolabeled nanoparticles were collected into
300-400 μL of phosphate buffered saline by centrifugation.
Animal model establishment
All experiments were carried out under protocols approved by the
Institutional Animal Care and Use Committee. Our mouse model was based on
one reported by Berr’s group.58 Female FVB mice (Jackson Laboratory) aged 6-8
weeks received weekly intraperitoneal (IP) injections of 1 mg urethane/g body
weight dissolved in sterile 0.9% NaCl. Twenty weeks after the initial urethane
injection, MRI was used to verify lung tumor presence. PET imaging was
performed when at least one lung tumor reached 1.5 mm in diameter.
MRI and PET Animal imaging
Twenty-four weeks after urethane treatment, lung tumor bearing mice
were first imaged on a 7 Tesla ClinScan MRI system (Bruker BioSpin
Corporation, Billerica, MA), Inc., Palo Alto, CA). MRI were acquired with a
cardiac and respiratory gated, multi-slice, spin-echo sequence developed in our
lab with the following parameters: field of view 30 mm, effective matrix = 192 ×
192 zero-filled to 256 × 256, slice thickness 0.7 mm, TR was a function of the
breathing cycle and averaged to about 1 second. The TE was 11ms, the number
of averages was 4, and the number of slices was 15 with a gap equal to 0.7mm
between slices to avoid crosstalk. The slice stack was moved by 0.7mm and 15
other interleaved slices were acquired. Gadolinium-DTPA contrast agent
(Magnevist; Bayer Schering Pharma, Berlin, Germany) was injected at a dose of
50 mmol/kg body weight in the hind leg muscle. Before PET imaging, mice were
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injected with 64Cu-labeled GoMe nanoparticles via the lateral tail vein. Each
mouse received 500-750 μCi of 64Cu for a total volume of 150-200 μL. Mice
were imaged using a Focus 120 PET scanner (Positron Emission Tomography)
(Siemens, Knoxville, TN) at 6 h and 20 h post administration. During the 40 min
PET acquisition, anesthesia was maintained using 1.25% isoflurane in O2 inhaled
through a nose cone. Heart rate, respiration, and rectal temperature were
monitored (SAII, Stony Brook, NY). PET data were reconstructed using OSEM
algorithm with 2 iterations and 12 subsets followed by MAP algorithm (18
iterations). The reconstructed image (not corrected for attenuation) was
composed of 95 axial slices of thickness 0.79 mm with an in-plane voxel
dimension of 0.4 mm × 0.4 mm (128 × 128 pixels).
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Figure 2.1 Schematic illustration of the fabrication of GoMe. (A) The preparation
scheme of GoMe. (B-D) TEM images of MSN, PEG-GNS, and GoMe
nanoparticles. Scale bars are 50, 10, and 50 nm in (B), (C), and (D), respectively.
The inset in (B) shows the TEM image of one individual MSN.
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Figure 2.2 Nitrogen adsorption isotherm for MSN. The insert shows the pore size
distribution.
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Figure 2.3 SEM image of GoMe. Image was acquired with a Zeiss Ultra Plus
FESEM at the magnification of 300,000 ×.
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Figure 2.4 SEM-EDX analysis of MSN-SH.
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Figure 2.5 SEM-EDX analysis of GoMe.
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Figure 2.6 The surface charge of MSN, GNS, GoMe, and DOX@GoMe.
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Figure 2.7 Size distribution of GoMe in 10% FBS.
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Figure 2.8 Reaction monitoring of GNS conjugation to MSN with UV and TEM.
The UV-Vis spectra of GNS, MSN, and their mixture after 12 and 24 h of reaction
(A), as well as their photothermal heating curves upon 10 min of 808 nm laser
irradiation (2.83 W/cm2) (B). TEM images of GoMe formed after 2 h (C), 12 (D),
and 24 h (E) of mixing GNS and MSN. Scale bars are 50 nm in (C), (D), and (E).
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Figure 2.9 The photothermal effect of GoMe at different concentrations. Nanosuspension of GoMe was irradiated by the 808 nm laser (2.83 W/cm2).

70

Figure 2.10 Real-time temperature elevation of GoMe and GNR nanosuspensions during 7 cycles of NIR irradiation. GoMe and GNR were irradiated
with an 808 nm NIR laser for 10 min (2.83 W/cm2) and then cooled down for 20
min. The last cycle was carried out 24 h after the 6th cycle.
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Figure 2.11 The photothermal effect of GoMe in medium with or without GSH.
Nano-suspension of GoMe was irradiated by the 808 nm laser (2.83 W/cm2, 10
min on and 20 min off).
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Figure 2.12 The UV-Vis spectra and TEM images of GoMe and GNR changed
due to repeated photoirradiation. The UV-Vis spectra (A) and TEM images of
GoMe (C, D), and the UV-Vis spectra (B) and TEM images of GNR (E, F). TEM
images of GoMe before laser irradiation (C) and after 5 cycles of irradiation
induced heating/cooling (D). TEM images of GNR before laser irradiation (E) and
after 5 cycles of irradiation induced heating/cooling (F). Red arrows indicate
those GNRs changed to round shape (F). Scale bars are 50 nm in all images.
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Figure 2.13 The release kinetics of GoMe in different conditions. In plain PBS or
PBS supplemented with GSH (A) and under the trigger of NIR irradiation (B). The
red arrows indicate the time points when the irradiation (10 min, 2.83 W/cm2) was
applied.
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Figure 2.14 The uptake of DOX@GoMe by confocal and dark-field microscopy.
The confocal (A-F) and dark-field (G-J) images of A2058 cells co-cultured with
DOX@GoMe. Cells in A-C, and G-H were control. Cells in D-F, and I-J were
treated with DOX@GoMe. Images H and J were collected in dark-field mode.
Scale bars in A-J are 10 μm.
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Figure 2.15 The real-time medium temperature during NIR laser irradiation of
different GoMe concentrations. GoMe concentration was calculated based on
corresponding DOX concentration.
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Figure 2.16 Cytotoxicity of DOX@GoMe coupled with NIR irradiation. The
fluorescent images of live/dead cell assay (A-C) after NIR irradiation and the
cytotoxicity of DOX@GoMe coupled with NIR irradiation (10 min, 2.83 W/cm2)
(mean ± SD, P < 0.05 *; P < 0.01 #). Cells in A, B, and C were treated with blank
medium, blank GoMe, and GoMe coupled with NIR irradiation, respectively.
Scale bars in A-C are 50 μm. (D) Cytotoxicity of various treatment in UMSCC
22A cells.
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Figure 2.17 MRI and PET animal imaging. (A) Four contiguous MRI transverse
images, (B-D) PET images of 3 tumors in the lung of mouse received
radiolabeled GoMe. Tumors are indicated by yellow arrows in (A). (B) PET
images of contiguous slices in transverse acquired 6 h post administration.
Tumors are indicated by green arrows in (B). Whole body PET images acquired 6
h (C) and 20 h (D) post administration.
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Figure 2.18 1H-NMR of PEG-GNS and the UV-Vis spectra of PDAGNS. (A) 1HNMR of PEG-GNS in D2O. (B) The UV-Vis spectra of PDA-GNS.
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CHAPTER 3
Sigma receptors targeted GoMe for cancer photothermal therapy and
photodynamic therapy
ABSTRACT
Although various nanocarriers have been developed to treat cancer, how
to use a multifunctional nano-carrier to treat cancer patients more efficiently and
personalized remains to be a challenge. Here, we present a gold nanoparticle
conjugated mesoporous silica nanoparticles hybrid (GoMe) as a carrier for Pc 4.
The results show that GoMe actively targets sigma 2 receptors overexpressing
cancer cells, and rapidly releases Pc 4 inside cancer cells upon the high reducing
intracellular environment or external laser irradiation. Pc 4 coupled with 660 nm
laser irradiation generates singlet oxygen in the mitochondria of oxygen-rich
tumor tissues and initiates the subsequent cell apoptosis or necrosis, and the
remaining tumor cells in hypoxia regions are killed immediately upon subsequent
808 nm laser irradiation toward GoMe. Our study shows that GoMe is superior in
inhibiting cross-resistance with any other chemotherapy, and more importantly, it
is highly efficient in eradicating tumors in UMSCC 22A xenograft mice model.
Our design can serve as the site specific anti-cancer therapy and be a promising
candidate for clinical use.
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INTRODUCTION
Photodynamic therapy (PDT) is a clinically approved effective strategy
against various malignant cells.59 Three elements are essential in the application
of PDT, light, photosensitizer (PS) and oxygen. It’s a two-stage reaction process:
Firstly, PS is applied in the disease foci and exposed to light at a specific
wavelength corresponding to the type of PS. Then, energy transferred from the
light by PS will initiate a series of consequences at the presence of oxygen which
will eventually cause the cell apoptosis or necrosis, systemic immune reaction
and destruction of microvasculature. The major advantage of PDT is its unique
oxygen-dependent tumor cells eradiation mechanism, which is unlikely to
generate cross-resistance with other therapies.60 It is especially beneficial for the
tumor that is inoperable. Another advantage of PDT relies on its boosting
systemic immunity function.61 Until now, there are over 200 clinical trials using
PDT in the field of skin melanoma, head and neck, non-small lung, bladder,
ovarian, and brain cancers.62
However, the application of PDT in anticancer is greatly impaired by the
requirement for the rich oxygen environment, which is not always available in
solid tumor microenvironment. A solid tumor is composed with mild to severe
hypoxia regions as well as re-oxygenation regions. With the dynamic oxygen flow
occurring within these tumor areas through the chaos position of newly
generating vasculatures, it can greatly reduce therapeutic potential of PDT.63 In
addition, PDT induced the destruction of tumor vasculature will cause oxygen
depletion and increase hypoxia areas. In order to maximize the efficacy of PDT,
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it’s crucial to deliver and maintain a therapeutic level of PS in all tumors and to
reduce its liability on the oxygen level.
Abundant trials have been performed by either modulating the light
delivery or applying an excessive oxygen during PDT.64 In order to achieve a
higher oxygen level in tumor foci, patients who were receiving PDT were
maintained under the hyperbaric oxygen condition. The combination of PDT and
hyperbaric oxygen supply elongates the mean survival time for patients with
squamous cell carcinoma or adenocarcinoma.64c Instead of continuous
illumination, disrupting illumination in two fractions with refractory interval was
practiced on the rats bearing U87 human primary glioblastoma tumor and results
showed a severe necrosis in tumor tissue, indicating a better therapeutic
effect.64b Nanomedicine was developed to overcome these challenges, and
polymer based nanoparticles,65 carbon nanodots,66 and superparamagnetic iron
oxide nanoparticle67 were good candidates to deliver PDT. More recently, a codoped nanoparticle was developed to co-deliver PS H2TPyP and
chemotherapeutic agent curcumin to treat A549 human alveolar adenocarcinoma
xenograft mice model. They successfully reduced the tumor volume by 74%
through daily injection of the nanoparticle.68
Here we developed a new nanocarrier that combined PDT and
(photothermal therapy) PTT by loading Pc 4 into gold nanoparticle-mesoporous
silica nanoparticle hybrid (GoMe). The GoMe was able to efficiently and
specifically enter cancer cell through sigma 2 receptor mediated endocytosis and
maintain a stable and controlled dose of Pc 4 required for PDT in the tumor foci,
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and completely eradicate cancer cells with minimized side effects. Intracellular
GSH level or low pH environment in lysosome would trigger the release of Pc 4,
and upon the irradiation of a 660 nm laser, cells containing Pc 4 were killed
through either ROS induced cell apoptosis or necrosis. Cells in the hypoxia areas
survived from PDT were immediately burned by 808 nm photoirradiation. We first
tested the physical properties and biocompatibility of GoMe in physiological
environment, and examined the dual responsiveness of Pc 4 GoMe to
intracellular high redox potential environment and external photoirradiation.
Secondly, we elucidated the subcellular targets of MBA Pc 4 GoMe and its
mechanism of producing reactive oxygen species. Last, we validated the
synergistic efficacy of PDT and PTT of these nanoparticles in UMSCC 22A head
and neck bearing xenograft mice.
Results and discussion
Synthesis of MBA PC 4 GoMe
Silicon phthalocyanine Pc 4 is used to treat squamous cell carcinoma and
skin cancer in various clinical trials. Pc 4 GoMe was prepared by conjugating Pc
4 loaded MSN with gold nanospheres. Pc 4 loaded MSN was evenly covered by
PEG-SH (Mw=3400) stabilized gold nanosphere.69 TEM revealed that the final
diameter of GoMe reached 50 nm (Figure 3.2B). The UV absorbance of Pc 4,
PC 4 MSN or Pc 4 GoMe appeared at 680 nm (Figure 3.2F), suggesting that the
efficient Pc 4 based PDT should occur upon a 660 nm laser irradiation.
To conjugate targeting moiety to Pc 4 GoMe, 4-methoxybenzoic acid
(MBA) modified PEG was synthesized through the EDC/NHS reaction between
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the amine in polymer NH2-PEG-Mal and the carboxylate group of MBA as shown
in Figure 3.1B. The successful conjugation of MBA to SH-PEG-Mal was
confirmed by 1H-NMR as shown in Figure 3.2E, where the existence of MBA was
evidenced by the peak at 7.8 ppm (2H). The quantification of MBA conjugation
efficiency was tested by TNBSA assay. By comparing the available free amine in
MBA-polymer PEG-Mal to that in NH2-PEG-Mal, we concluded that 85.62% of
the free amine in NH2-PEG-Mal was replaced by MBA.
MBA-Pc 4 GoMe didn’t exhibit an increased size comparing to Pc 4 GoMe
according to TEM and SEM, but DLS showed a slight increase (about 24 nm)
(Figure 3.2B-D and 3.3A). Comparing with Pc 4 GoMe, the surface charge of
MBA-Pc 4 GoMe was decreased from -1.13 mV to -2.93 mV (Figure 3.3A).
Photothermal response of Pc 4 GoMe
To evaluate the photothermal response of Pc 4 GoMe, we tested the
photothermal capacity of Pc 4 GoMe at different concentrations. The absorbance
at 450 nm was used to represent Pc 4 GoMe concentration, as it is an indicator
for the density of gold on the surface of MSN.70 As shown in Figure 3.3B, the
absorbance at 450 nm positively correlated with the concentration of Pc 4 GoMe.
When the OD at 450 nm was at 0.08, it was enough to generate the energy that
can heat the surrounding aqueous solution up for 14.2 °C, while with the OD
increasing to 0.65, it was able to reach 63 °C after 10 min irradiation (Figure
3.3C). The heat transducing efficiency was 28% based on Figure 3.3D. Neither
water, MSN, nor gold nanoparticle themselves were able to generate enough
heat to reach comparable temperature elevation (data not shown). PC 4 GoMe,

84

as we previously proved, is a thermal stable nano-carrier that can maintain its
integrity upon intensive and repetitive irradiation.69 If the cancer cells have not
been completely eradicated in any scenario, a repeatable PTT can be applied
without any additional dose.
Colloidal stability and release behaviors of Pc 4 GoMe
The strong advantages of this system lie in its colloid stability during
circulation and responsiveness to intracellular signal and external NIR irradiation.
The premature release of Pc 4 in blood circulation or in the undesirable tissue
would lead to decreased bioavailability for target site and increased skin
sensitivity toward light.71 Our design can avoid this risk by sealing the Pc 4 inside
the pore channels of MSN during circulation. Once it enters the targeting cancer
cells, Pc 4 can be released by two mechanisms: firstly, intracellular high redox
potential partially cleaves the disulfide bond and loosen gold on the surface of
MSN, which induces release of Pc 4. Second, Pc 4 release can also be switched
on by NIR irradiation at 808 nm on GoMe, where an intensive heat will be
generated and followed by Pc 4 release. Figure 3.4A showed that with the
addition of 10 mM GSH in medium, Pc 4 GoMe doubled its release at the first
hour of incubation and released over 50% of its loading by the end of 24 h. In
addition, it was confirmed that Pc 4 GoMe showed a complete release of Pc 4
after laser irradiation at 808 nm for 10 mins, indicating that Pc 4 is able to
completely escape from the hybrid nanoparticle structure after PTT (Figure
3.4B).
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Colloidal stability is an important indicator for the destiny of administered
NPs in vivo, in which aggregated nanoparticles will alter drug pharmacokinetics,
toxicity and biodistribution. We used several media to estimate Pc4 GoMe
stability, including different concentrations of serum containing DMEM media and
PBS considering of the potential effects of ion strength and protein adsorption.
Pc 4 GoMe at the concentration of 100 µg/mL in 10% FBS containing DMEM
media showed no significantly increase in hydrodynamic size for up to one week
(Figure 3.4D). Meanwhile, we also investigated the release of Pc 4 during this
period and found that in 10% serum containing medium at 37 °C, Pc 4 only
released less than 10% of its loading by the end of 48 h. In 50% serum medium,
Pc 4 would only release around 30% at the end of 48 h incubation (Figure 3.4C).
Therefore, Pc 4 GoMe was not prone to aggregate in circulation and showed an
excellent serum compatibility.
Reactive oxygen species
PS can produce ROS through type I and type II reaction. For Pc 4, it
mainly goes through the type II reaction. Instead of directly producing hydroxyl
and superoxide radicals, it reacts with tissue oxygen and produces singlet
oxygen upon excitation.72 We evaluated the capability of PC 4 GoMe in
generating singlet oxygen using both 9,10-dimethylanthracene (DMA) and SOSG
assays.73
DMA reacts with 1O2 (singlet oxygen) and forms non-fluorescent 9,10endoperoxide.74 Figure 3.5A revealed that the fluorescence of DMA decreased
with the co-incubation of Pc 4, Pc 4 GoMe or Pc 4 GoMe with GSH. The
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decrease of DMA fluorescence at 432 nm was proportional to the photoirradiation
duration. Longer co-incubation with GSH (16 h) was able to diminish the
fluorescent intensity by 61.4%, almost reaching the activity of free Pc 4.
To further study the singlet oxygen generating capacity of the
nanoparticle, fluorescently-quiescent SOSG which can react specifically with
singlet oxygen and produce a fluorescent SOSG-endoperoxide molecules was
employed. Figure 3.5B-E showed the Pc 4 generated the highest singlet oxygen
level after photoirradiation, and Pc 4 GoMe generated 73% of singlet oxygen
compared with free Pc 4. However, 24 h of GSH pretreatment boosted the singlet
oxygen generating capacity of Pc 4 GoMe to 90% of that of free Pc 4.
As evidenced from the above in vitro results, Pc 4 GoMe was nearly as
effective as free Pc 4 in generating singlet oxygen after GSH treatment. We
further evaluated the intracellular oxygen species levels induced by Pc 4 GoMe.
As we discussed earlier, the intracellular GSH level is significantly higher than
that of the extracellular matrix. It is expected that after the internalization of
nanoparticles, GSH would trigger the release of Pc 4, which can generate singlet
oxygen upon photoirradiation. Since SOSG itself is a weak photosensitizer,
various controls were employed to exclude the effect of either SOSG, NIR or Pc
4 themselves. Without NIR, neither Pc 4 nor Pc 4 GoMe could generate
detectable signals of oxidized SOSG. In response to NIR, they generated a
strong green fluorescence indicating the abundant existence of intracellular
singlet oxygen. In addition, there was no significant difference among the Pc 4,
Pc 4 GoMe and MBA Pc 4 GoMe groups (Figure 3.6).
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Cellular uptake of MBA Pc 4 GoMe
Sigma 2 receptors were overexpressed in UMSCC 22A cells. Therefore,
MBA with high affinity to sigma 2 receptors was chosen as the targeting moiety
for UMSCC 22A cells.32b, 75 In our study, the targeting moiety MBA was
conjugated on the surface of nanoparticles, which ensures its availability when
nanoparticle was exposed to cells. To investigate the internalization efficiency of
MBA Pc 4 GoMe, UMSCC 22A cells were treated with free drug or GoMe or MBA
GoMe and examined with FACS and confocal microscopy. Figure 3.7A showed
that longer co-incubation led to an increased internalization of Pc 4 into cells at
37 °C. Both Pc 4 GoMe and MBA Pc 4 GoMe treatments showed a better uptake
than free Pc 4. MBA Pc 4 GoMe showed the highest uptake, where over 40% of
Pc 4 was internalized inside cells compared with free Pc 4 (Figure 3.7A-C).
Previous research showed that hydrophobic PS enters cells by the
incorporation into lipoproteins such as low density lipoproteins (LDL) and
followed by LDL-receptors dependent endocytosis76 and MBA Pc4 GoMe enters
cell through sigma 2 receptor mediated endocytosis. Since the endocytosis is an
energy dependent process, a lower temperature would reduce the uptake of Pc 4
or Pc 4 GoMe.77 We compared the uptake behaviors of these nanoparticles at 4
°C and observed a significantly decrease of Pc 4 uptake (Figure 3.7D-F). The
uptake of MBA Pc 4 GoMe group was reduced mostly by the lower temperature,
suggesting that the internalization of MBA Pc 4 GoMe relied on endocytosis
mostly.
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Confocal microscopy was employed to study the role of MBA in MBA Pc 4
GoMe internalization. As shown in Figure 3.7G, with the addition of free MBA,
the total Pc 4 uptake was significantly inhibited. It is suggested that the free MBA
was able to partially block the accessibility of sigma 2 receptors, which
subsequently interfered the interaction of MBA Pc 4 GoMe with the cells and
negatively impacted its uptake.
Characterize PDT of Pc 4 GoMe for UMSCC 22A cells
We have shown that MBA Pc 4 GoMe enters the cells more efficiently
than Pc 4 GoMe and Pc 4. We then tested whether enhanced uptake of Pc 4
resulted in better photodynamic therapy. After Pc 4 entered cells, it primarily
located in the mitochondria 2 h after treatment.78 PC 4 PDT induces cell
apoptosis and necrosis by photodamaging two antiapoptotic proteins Bcl-2 and
Bcl-Xl. These proteins interacts with mitochondrial permeability transition pore
complex and governs mitochondrial death pathway partially through controlling
cytochrome C release. To test whether Pc 4 GoMe can enter mitochondria,
confocal microscopy was applied to track Pc 4 intracellularly (Figure 3.8A). We
compared the overlap of Pc 4 and mitochondria channels in the treatment of Pc
4, Pc 4 GoMe or MBA Pc 4 GoMe, and found that the orange signals in both Pc 4
GoMe and MBA Pc 4 GoMe were significantly stronger than that in free Pc 4
treated cells. Among these groups, MBA Pc 4 GoMe showed the highest
accumulation in mitochondria. Since the loss of mitochondrial membrane
potential (ΔΨm) is a critical step for cytochrome C release,79 we monitored the
ΔΨm change quantitatively with JC-1 dye by measuring the ratio of the red
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fluorescent intensity to green fluorescence intensity. JC-1 dye can selectively
enter mitochondria, and exist in either aggregation or monomer form depending
on the health status of mitochondria: If the mitochondria are in the healthy form,
mitochondrial membrane potential will maintain a high level and JC-1 stays in
aggregation form and displays red fluorescence; otherwise, JC-1 will be in form
of monomer and show green fluorescence. After PDT for cells treated with 1 µM
Pc 4, the ratio of JC-1 aggregation form to JC-1 monomer form decreased from
14.81 to 5.64 in free Pc 4 treated cells, while this ratio for cells treated with Pc 4
GoMe dropped to 9.84, indicating that mitochondria was damaged in response to
PDT (Figure 3.8B and C).
Synergistic effects of PDT and PTT on the viability of cancer cells
To validate the direct cytotoxic effect of PTT and PDT, a live/dead staining
assay was carried out on cells after exposure to PDT, PTT, or the combination of
PDT and PTT. The ethidium homodimer-1 in the kit, an indicator of loss of
plasma membrane integrity, can distinguish between dead (Red) and living
(Green) cells. Figure 3.9A-H represented the acute consequence of PDT and
PTT on UMSCC 22A cells that had been incubated with Pc 4, Pc 4 GoMe or
MBA Pc 4 GoMe for 3 h. The PDT and PTT were administered by irradiating cells
with a 660 nm laser and the 808 nm laser, respectively. Neither control cells nor
free Pc 4 treated cells show noticeably cell death in response to the PDT or the
combination of PDT and PTT (Figure 3.9A and B). Pc 4 GoMe and MBA Pc 4
GoMe treated groups also did not increase the cell death in response to PDT
(Figure 3.9C-F). It might be because a short period after PDT is not sufficient to
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generate enough pro-apoptotic factors.80 PTT can kill cancer cells more rapidly
as shown in Figure 3.9G and H. Pc 4 free drug did not show dual laser induced
cytotoxicity, while GoMe eradicated cancer cells more efficiently in response to
dual laser suggesting a PTT and GoMe dependent mechanism for cell killing.
To further evaluate the synergistic effects of PDT and PTT in Pc 4 GoMe,
we tested the PDT/PTT effect on UMSCC 22A and A 2058 cells using MTT cell
viability assay. In this experiment, skin cancer and head and neck cancer cells
were chosen due to the practical clinical application of Pc 4 as mentioned earlier.
The cytotoxicity of Pc 4 GoMe or MBA Pc 4 GoMe on A 2058 or UMSCC 22A
without any photoirradiation was negligible at Pc 4 concentration ranging from 25
to 500 nM, suggesting low side effects and high compatibility (data not shown).
With the PDT alone, Pc 4 killed 64% UMSCC 22A cells and 59% of A 2058 cells
at 500 nM under 200 mJ/cm2 laser irradiation. At the same Pc 4 concentration,
Pc 4 GoMe killed about 30% cells, which was less effective compared to free Pc
4. MBA Pc 4 GoMe showed similar cell killing effect to free Pc 4 in UMSCC 22A
(Figure 3.9I) and A 2058 cells (Figure 3.9K). Taking together the enhanced
cellular uptake of MBA Pc 4 GoMe, we can conclude that MBA induced the
accumulation of MBA Pc 4 GoMe inside sigma 2 overexpressing cancer cells and
led to stronger PDT effect.
Next, we tested if the combination of PDT and PTT shows synergistic
effect and if the sequence of two therapies matters in killing cancer cells. Figure
3.9J showed that at low concentration, Pc 4 GoMe treated cells showed almost
no cell killing if applied PTT first followed by PDT, while MBA Pc 4 GoMe was
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able to kill 38% of cancer cells. But if PDT was applied first and followed by PTT,
Pc 4 GoMe dramatically increased its efficacy. Surprisingly, MBA Pc 4 GoMe
was able to kill around 95% of cells even at low concentration if cells were first
receiving PDT followed by PTT (Figure 3.9J). In A 2058 cells, we only test the
PTT followed by the PDT therapy (Figure 3.9L). With this combination MBA Pc 4
GoMe was able to achieve an 83% of cell death, which was superior to Pc 4
GoMe or Pc 4. Such cytotoxicity results clearly proved the advantages of
combination of PDT and PTT in treating various cancer cells, especially at the
sequence of application with PDT followed by PTT. We speculate that when
applying PTT first, GoMe generates high temperature that may exclude some
oxygen out of the cancer cell environment, thus greatly reduces of PDT effect.
The sequence that PDT followed by PTT can cause remarkable cell death due to
the direct interaction of heat with PDT affected the tumor cells. In addition, if
applied in vivo, it is expecting that the sequence is more important as severe
tumor hemorrhage would occur due to the initial heat from PTT which hampers
the efficacy of PDT.
In vivo antitumor efficacy
To evaluate the in vivo antitumor effect of GoMe, we divided UMSCC 22A
bearing nude mice into 6 groups: saline, Pc 4 with PDT, Pc 4 GoMe with PDT,
MBA Pc 4 GoMe with PDT, Pc 4 GoMe with dual photoirradiation and MBA Pc 4
GoMe with dual photoirradiation. All the treatments were well tolerated as mice
bodyweight remained the same throughout the whole period (Figure 3.10A).
Tumors in control group increased by 15 times compared to their sizes at the
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beginning of the treatment. Comparing to the control, the mice treated with Pc 4
GoMe or MBA Pc 4 GoMe alone with PDT slowed the growth of tumor, indicating
an inhibited tumor progression (Figure 3.10 B-E). It has been reported that tumor
that survived from PDT will start to regrow in 4-5 days after PDT or 6-7 days after
the combined PDT and hyperthermia therapy.81 Surprisingly, Pc 4 GoMe or MBA
Pc 4 GoMe coupled with dual laser irradiation completely eradicated the tumor,
and tumors failed to recur over 28 days post treatment, (Figure 3.10B and C).
There were no significant difference between MBA Pc 4 GoMe and Pc 4 GoMe
after dual laser irradiation. Figure 3.10C showed that Pc 4 alone with PDT, MBAPc 4 GoMe with PDT, and Pc 4 GoMe with PDT achieved 64.4%, 91.04%, and
58.56% tumor growth inhibitory effect, respectively. In contrast, MBA-Pc 4 GoMe
coupled with dual laser treatment achieved over 99% tumor growth inhibitory
effect.
Histology were carried out on the tumors (Figure 3.11A) and livers
(Figure 3.11B) of the mice with different therapies. Tumor tissues were isolated
and examined with H&E staining. There was clear necrosis or apoptosis sign in
the tumor tissues from the dual laser treatment compared to the control, and we
did not observe liver damage or inflammation lesion, suggesting the liver function
was not hampered by MBA Pc 4 GoMe.
CONCLUSION
For currently available cancer therapy, PDT is widely used as an auxiliary
strategy to enhance chemotherapy or radiotherapy. As early as 1988, there are
abundant studies reported that the combination of chemotherapy and PDT
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together would lead to an enhanced antitumor effect in murine model.82 However
the drawbacks of PDT in heavily relying on oxygen level and inability to eradicate
cancerous cells failed to prevent the recurrence of tumor. Recently studies have
been practiced to combined PDT with PTT using various nanocarriers to achieve
higher potency against cancer cells. The synergistic combination can be
achieved by co-administering gold nanoshell together with porphyrin,83 or by
combination of chlorin e6 and poly(dopamine).84 Despite of the progress, more
effects are needed to enhance the synergistic effect of PDT and PTT. In this
study, we have developed a sigma 2 receptor targeted Pc 4-loaded nano-carrier
for photodynamic therapy and photothermal therapy. The PDT effect can be
enhanced by regulating the PS distribution and accumulation inside cancerous
cells. With the combination of PTT, the cancer cells were killed over 95% in vitro
and in vivo experiment showed complete cancer cell eradiation after the dual
laser therapy. Additionally, the active targeting to sigma 2 receptor
overexpressing cancer cells further amplify the therapeutic effect. This nanocarrier is good in relieving the heavy burden of PDT on oxygen levels and will not
confer any cross-resistance if any other adjuvant therapy is applied.
MATERIALS AND METHODS
Materials
Terraethylorthosilicate (TEOS), (3-mercaptopropyl)trimethoxysilan)
(MPTMS), hexadecyltrimethyl ammonium bromide (CTAB), sodium hydroxide
(NaOH), pluronic®F-127, 9,10-dimethylanthracene (DMA), tween-80, Ammonium
nitrate, methanol, gold chloride trihydrate, cysteamine hydrochloride, 2,2-dipyridyl
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disulfide, triethylamine (TEA), glutathione (GSH), 4-mercaptobenzoic acid (MBA),
thiazolyl blue tetrazolium bromide (MTT) and sodium borohydride (NaBH4) were
purchased from Sigma-Aldrich. PEG2000-SH was purchased from Laysan Bio.
Maleimide -PEG-NH2 (Mw=3400) was purchased from Creative PEGworks.
Ethanol and acetic acid were acquired from Fisher Scientific. Silicon
phthalocyanine Pc 4 was obtained from NIH. Live and dead staining kit, SOSG
was obtained from Thermofisher Scientific. JC-1 Mitochondrial Membrane
Potential Assay Kit was purchased from Cayman chemical.
Transmission Electron Microscopy (TEM) was conducted on a Hitachi
H8000 at an acceleration voltage of 200 KV. Scanning electron microscopy
(SEM) was conducted on a Zeiss Ultra plus FESEM at 6 KV. UV-vis spectrum
was obtained with a DU UV/Vis 650 (Beckman). 1H-NMR was conducted in a
Bruker Avance III HD 300. Fluorescent Microscopy images were obtained with an
Olympus IX81 fluorescence microscopy. Confocal microscopy images were
obtained with a Carl Zeiss LSM 700. Flow cytometry was conducted in a
Beckman coulter FC500 flow cytometer.
Synthesis of PC 4 loaded GOME
MSN and gold nanoparticles were synthesized as described.69 Pc 4 was
dissolved in DMSO at 10 mg/ml and mixed with MSN at 5/100 weight ratio. After
the overnight stirring, un-encapsulated Pc 4 was removed by centrifugation and
followed by twice washing with H2O. To conjugate Au nanosphere to MSN, 800
µg of Pc 4 MSN was reacted with 2 nmol AU-PDA through thiol-disulfide bond
exchange reaction for 24 h and Pc 4 loaded GoMe was purified by washing with
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H2O twice. PC 4 loading content was determined by fluorescent plate reader (M2,
Molecular device) with excitation at 630 nm and emission 670 nm. The total
loading P4 amount was determined by triple washing in DMSO to completely
dissolve the encapsulated drugs with extensively sonicating.
Synthesis of polymer SH-PEG-MBA
MBA was conjugated with Mal-PEG-NH2 through EDC/NHS reaction. MBA
(5 mg in 0.4 mL DMSO) was added to EDC/NHS solution (2 equiv of MBA, 0.1 M
MES pH 6) and allowed for activation at r.t for 30 mins. Mal-PEG-NH2 (20 mg,
5.71 µM) was dissolved in DMSO/ pH 7.4 buffer. MBA activated solution (1.74
mg) was added to Mal-PEG-NH2 solution above. The reaction was carried out at
r.t for 24 h. Crude product was purified by dialysis for 24 h in DMSO followed by
dialysis in ddH2O for 24 h with a dialysis membrane (MWCO=1000 Da). The final
product was collected through lyophilization and stored at -20 ºC until use.
Polymer conjugation was confirmed by 1H-NMR using CDCl3 as the solvent and
the reaction yield was quantified with TNBSA assay by calculating the reduced
amine in the polymer.
Preparation of PC 4 GOME coated with SH-PEG-MBA
PC 4 GoMe was well dispersed in ddH2O at 1 mg/ml. SH-PEG-MBA was
dissolved in H2O at the concentration of 2 mg/ml and mixed with PC 4 GoMe
(1:2, w/w). The mixture was stirred and reacted for 24 h at r.t. MBA conjugated
PC 4 GoMe (MBA-PC 4 GoMe) was isolated from unreacted SH-PEG-MBA by
centrifugation followed by washing with H2O twice. Final product was dispersed
in PBS or H2O at 1 mg/ml and stored at -4 °C prior for use.
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Characterization of MBA PC 4 GoMe
GoMe was diluted at the concentration of 20 µg/ml in H2O and 3 drops of
the suspension was loaded onto a 200-mesh copper grid coated with formvar.
Air-dry the grid and analyzed with TEM (Hitachi) using 200 K acceleration
voltage. GoMe was suspended in ethanol and drop on the silicon wafer. Air-dry
the wafer and analyzed with SEM with 6 KV under 200,000X magnification. The
UV/vis spectrum was recorded with a DU650. The size was determined with
dynamic light scattering and surface charge was recorded with a Malvern NanoZS Zeta Sizer.
Photothermal response
Pc 4 GoMe was diluted to a serial of concentrations with PBS and their
UV-Vis spectra were recorded. The Pc 4 GoMe suspension with the volume of
200 µL in 1.5 mL eppendorf tube was irradiated with an 808 nm laser for 10 min
(Scorpius D-700 laser, 2.83 W/cm2). The temperature of the suspension was
monitored simultaneously with a FLIR i7 thermal imaging camera and recorded
every 30 sec. The cool period followed by irradiation was recorded up to 20 mins
or until it completely decreased to r.t.
In vitro release of Pc 4 from Pc 4 GoMe
To test the responsiveness of Pc 4 GoMe to intracellular high reducing
environment, PBS plus 10 mM GSH were employed. Due to the solubility
limitation of Pc 4, 1% tween was added to above solutions. Two hundred
microliter of Pc 4 GoMe (at 1 mg/mL MSN) was loaded to 1.5 mL eppendorf tube
and diluted with 1 mL PBS or GSH supplemented PBS. At each time point,
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samples were centrifugal at 16000 rcf for 10 mins and all the supernatant was
transferred out and 1 mL of fresh media was supplemented in.
To stimulate the laser trigger of Pc 4 GoMe, Pc 4 GoMe suspension was
photoirradiated by NIR 808 nm laser for 10 mins after 24 h suspension in serum
containing PBS buffer at 37 °C. The release of Pc 4 GoMe was continued to be
monitored for another 24 h. At pre-determined time point, GoMe was centrifuged
and all the supernatant was collected. The concentration of Pc 4 was determined
by fluorescent plate reader, using the same release buffer as diluting buffer when
preparing standard curves for Pc 4.
Stability testing of Pc 4 GoMe
Nanoparticles at the final concentration of MSN at 100 µg/mL were
suspended in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine
serum (FBS) at 37 °C. The size of nanoparticles was measured with DLS. To
further investigate the integrity of GoMe during the circulation in physiological
environment, the release behaviors of Pc 4 GoMe was tested in two release
media. GoMe were incubated with PBS containing 10% or 50% of FBS at 37 °C
via rotation (Thermoscientific tube revolver, 10 rpm) for different time points
varies from 1 h to 48 h. At each time points, the released Pc 4 were collected
through centrifugation and determined by a fluorescent plate reader.
Quantification of cellular uptake of GoMe
Cellular uptake of Pc 4 GoMe or MBA Pc 4 GoMe was quantified by flow
cytometry and confocal microscopy. Cells were seeded in 12 well plates at
200,000 cells per well and treated with Pc 4, Pc 4 GoMe or MBA Pc 4 GoMe at
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the concentration of 1 µM for 0.5 h, 1 h or 2 h. Cells were incubated at 4 °C or 37
°C, respectively. At each time point, cells were washed 3 times with cold PBS to
remove un-bounded Pc 4 or Pc 4 GoMe. Cells were collected and fixed in 4%
formaldehyde, and examined by FACS.
To further investigate the role of MBA in facilitating the uptake of
nanoparticles, the competition assay was carried out and the results were
obtained with confocal microscopy. UMSCC 22A cells were pre-incubated with
MBA (0.1 mg/mL) for 1 h. Different treatment groups were then added into each
petri dish and reached the final Pc 4 concentration of 1 µM. After the coincubation of 3 h, cells were washed for 3 times and images were taken with
Zeiss 710 LM at Pc 4, DAPI and DIC channels.
Subcellular trafficking of Pc 4 GoMe
Subcellular localization of NPs affects the efficacy of a photosensitizer,
especially when mitochondria are the critical targets of Pc 4-PDT. Here we used
confocal microscopy to investigate the subcellular location of Pc 4 in UMSCC
22A cells. Cells were seeded in 10 mm petri dishes at 200,000 cells per dish, and
were allowed to grow overnight. Cells were treated with Pc 4, Pc 4 GoMe or MBA
Pc 4 GoMe at the Pc 4 concentration of 500 nM and incubated for 3 h. Cells were
washed with PBS for three times and incubated with Mitotracker red FM (100
nM) for 30 mins. Cells were then washed with PBS twice and incubated with
Hoechst 33342 (1 µg/mL) for 10 mins. Images were taken immediately with
confocal microscopy.
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Singlet oxygen detection in vitro
In order to investigate the singlet oxygen level upon laser irradiation, two
fluorescent dyes N,N-dimethylacrylamide (DMA) and singlet oxygen sensor
green (SOSG) were employed. Briefly, Pc 4 or Pc 4 GoMe at the concentration of
112 nM was dispersed in PBS or PBS supplemented with 10 nm GSH,
respectively. To create a sink condition, the above media were supplemented
with 0.5% tween 80. Stock solution of DMA was prepared in DMF at
concentration of the 250 µM. Three milliliter Pc 4 or Pc 4 GoMe was mixed with
DMA at the final concentration of 16.7 µM and kept stirring at r.t. The mixture was
kept in vial with a cap opened and was irradiated with a 660 nm laser
continuously for 10 mins. Two hundred microliter was sampled out every minute.
The fluorescent intensity decay of DMA was analyzed (ex: 375 nm, em: 435 nm).
Fluorescent intensity at 0 mins was defined as the mixture of Pc 4 with DMA
without NIR irradiation.
Fluorescent dye singlet oxygen sensor green (SOSG, Thermofisher
scientific) were also applied to determine the singlet oxygen level. Briefly, Pc 4 or
Pc 4 GoMe at the Pc 4 concentration of 1 µM was suspended in PBS containing
1% tween 80. One hundred microliter suspension was added to a black 96 well
plate (Costar), followed by the addition of 20 µl SOSG solution (stock solution
prepared in methanol and diluted with HBSS buffer with a final concentration at
50 µM). Each plate was irradiated with a 660 nm laser (18 mW/cm2) for 2, 6, 8 or
10 mins and the control group was employed with the same amount of
nanoparticles or Pc 4 without laser irradiation. The oxidized SOSG was
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determined by measuring the fluorescent intensity at 525 nm upon the excitation
at 504 nm. The full spectrum was recorded from 500 nm to 600 nm when excited
at 490 nm with cutting off at 515 nm. SOSG assay was further employed to
examine the Pc 4 responsiveness to GSH triggering. Pc 4 GoMe was incubated
with 10 mM GSH for 3 h prior to NIR irradiation, and the fluorescent intensity at
525 nm and full spectrum were recorded as described above. All experiments
were carried out in triplicate.
SOSG assay was also employed to investigate the intracellular singlet
oxygen production. UMSCC 22A cells were seed in 12 well plate. When cell
reach nearly confluence, Pc 4 GoMe, MBA Pc 4 GoMe or Pc 4 at the Pc 4
concentration of 1 µM was added to each well and allowed to incubated for 16 h.
Cells was then washed with PBS twice and incubated with SOSG solution for 2 h
(HBSS solution at concentration of 1 µM). Cells were irradiated for 10 mins (660
nm, 18 mW/cm2), followed by imaging with fluorescent microscope with the GFP
channel and DIC channel.
Measurement of mitochondrial membrane potential
Changes of ΔΨm were monitored with JC-1 dye. Cells were seeded in 96
well with a black 96 well plate and allowed to reach the confluence of 80% before
the experiment. Cells were co-incubated with Pc 4, Pc 4 GoMe at the Pc 4
concentration of 200 nM or 1 µM for 16 h. Media was then replaced and cells
were irradiated with a 660nm laser at 200 mJ/cm2. After 5 h incubation, cells
were stained with JC-1 dye diluted media (10 µg/mL) for 30 mins. Afterwards,
cells were washed twice with assay buffer and the fluorescent intensities at the

101

excitation of 485 nm and the emission of 525 nm as well as the excitation at 535
nm and emission of 590 nm was recorded. Control plate was prepared in the
same method except without receiving laser irradiation.
Cell viability upon PDT and PTT treatment
To visualize the direct cytotoxicity effect of PTT or the combination of PDT
and PTT on cancer cells, a live/dead staining kit was employed. UMSCC 22A
were seeded in a 24 well plate at the density of 200,000 cell per well and allowed
for overnight incubation. Cells were treated with Pc 4, Pc 4 GoMe or MBA Pc 4
GoMe containing media (at the Pc 4 concentration of at 100 nM) for 3 h. After the
treatment, the old media were replaced by fresh media. Subsequently, cells
received different photoirradiation treatments including: 1) 660 nm PDT at 200
mJ/cm2, 2) 808 nm PTT for 10 mins, 3) firstly irradiated with PDT followed by
PTT. Media were removed and cells were stained with live/dead staining kit in
PBS for 30 mins according to manufacturer’s instruction. Images were taken
immediately with a fluorescent microscope with FITC, Texas red and DIC
channels.
Cell viability after receiving PDT and PTT treatment was quantitatively
evaluated by MTT assay. UMSCC 22A and A2058 cells were seeded at density
of 20,000 per well in 96 well plates with either transparent or black wells and
incubated at 37 °C under 5% CO2 overnight. Pc 4, Pc 4 GoMe or MBA Pc 4
GoMe at various concentration were incubated with cells in dark for 3 h. After
twice washing with PBS, cells received photoirradiation accordingly. For PDT
treatment groups, cells were seeded in black well clear bottom 96 well plates and
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irradiated under the laser (λ=660 nm, 200 mJ/cm2). For PTT treatment groups,
cells were seeded in clear 96 well plates and irradiated under the laser (λ=808
nm, t=10 mins). For the combination therapy of PDT and PTT, cells were either
first receiving PDT followed immediately with PTT, or first receiving PTT followed
by PDT. After the photoirradiation, cells were further incubated in dark for 48 h.
Afterwards, the old media were replaced with 100 µL fresh media containing 1
mg/mL MTT reagent and continued to incubate for 4 h. The formed MTT crystal
was dissolved with a stop solution and the finally optical density of the medium
was measured using a microplate reader (ELX808, Bio-Tech Instrument, Inc) at λ
= 595 nm.
Combination therapy in vivo
All animal experiments were conducted in accordance with NIH
regulations and approved by the Institutional Animal Care and Use Committee of
the University of South Carolina. Female athymic mice at 6 to 8 weeks (nu/nu)
were obtained from Jackson laboratory. UMSCC 22A cells were injected
subcutaneously into both flanks of mice (2 million cells per implant). The tumor
volume was measured by a digital capillary and calculated according to the
following formula: Tumor volume = (tumor length) × (tumor width) 2/2. When the
tumor reached to 50 mm3, mice were divided into 6 groups: (1) saline; (2) Pc 4
with PDT laser at the dose of 50 J/cm2, (3) Pc 4 GoMe was injected into tumor.
After the injection of 1 h, mice were treated with PDT at the dose of 50 J/cm2 for
the duration of 25 mins. (4) Pc 4 GoMe were injected into tumor. After the
injection of 1 h, mice were treated with PDT at the dose of 50 J/cm2. Immediately,
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the mice were then anesthetized and received PTT for 2 mins (808 nm, 2.8
W/cm2). (5) MBA Pc 4 GoMe was injected into tumor. After the injection of 1 h,
mice were treated with PDT at the dose of 50 J/cm2 (6) MBA Pc 4 GoMe was
injected into tumor. After the injection of 1 h, mice were treated with PDT at the
dose of 50 J/cm2. Immediately, the mice were anesthetized and received PTT for
2 mins (808 nm, 2.8 W/cm2). Pc 4 dose was kept at 0.5 mg/kg mice. At the end of
28 days, mice were sacrificed and tumors were harvested and weighed. The
isolated tumors were fixed in 10% neutralized formalin solution and changed to a
gradient of sucrose solutions until they sink down in the sucrose solution before
embedding with OCT. Tumor was sliced into 10 µm thickness and followed with
standard H&E staining protocol. The inhibition effect of tumor growth was
calculated based on the following equation: inhibition effect I (%) = (tumors
weight in the groups of saline - tumors weight in the treatment group)/ tumors
weight in the groups of saline × 100%.
Acute cytotoxicity of Pc 4 GoMe was evaluated in UMSCC 22A bearing
mice. After injection of the dose of Pc 4 GoMe or MBA Pc 4 GoMe, mice were
sacrificed in the next 24 hours. All the organs were collected and evaluated
through H&E stain histology for tissue sections.
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Figure 3.1 The scheme for the combination therapy of PDT and PTT using MBA
PC 4 GoMe (A) and the synthesis process of conjugating MBA to GoMe (B)
(Green ball-GoMe).
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Figure 3.2 Physical characterization of MBA Pc 4 GoMe. Transmission electron
microscope images of Pc 4-MSN (A), Pc 4 GoMe (B), MBA Pc 4 GoMe (C),
Scanning electron microscope image of PC 4 GoMe (D). (E) 1H-NMR of MalPEG-MBA in CDCl3. (F) The UV-Spectra of Pc 4, Pc 4-MSN, PC 4 GoMe and
MBA-Pc 4 GoMe.
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Figure 3.3 Hydrodynamic size and surface charge of Pc 4 GoMe and its
photothermal response. (A) Hydrodynamic size of MBA Pc 4 GoMe was
determined by dynamic light scattering, and surface charge was monitored by
Malvern nano sizer. (B) UV-Vis spectra of PC 4 GoMe at different concentrations.
(C) Photothermal response of Pc 4 GoMe at different concentrations coupled
with the 808 nm laser. (D) A heating and cooling cycle of PC 4 GoMe at OD =
0.65 in PBS.
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Figure 3.4 Pc 4 GoMe release and colloid stability. (A) The Pc 4 release kinetics
of Pc 4 GoMe. (B) The release of Pc 4 was in response to laser irradiation at 808
nm. Arrow represents the time point when the laser was applied. (C) Stability of
Pc 4 GoMe in serum containing media. (D) Hydrodynamic size changes of Pc 4
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Figure 3.5 Determination of singlet oxygen generation upon NIR 660 nm
irradiation. (A) DMA was used to determine the generation of singlet oxygen from
Pc 4 GoMe after the co-incubation with GSH 10 mM. (B) The fluorescence
intensity change of SOSG was used to determine the release of Pc 4 from Pc 4
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solution with Pc 4 GoMe with photoirradiation over time. (E) The spectra of
SOSG in solution with Pc 4 GoMe supplemented with 10 mM GSH after
photoirradiation over time. Both Pc 4 and Pc 4 GoMe solution mixed with SOSG
without photoirradiation were served as control.
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Figure 3.6 SOSG singlet oxygen detection in UMSCC 22A cells treating with Pc
4, Pc 4 GoMe and MBA-Pc 4 GoMe with or without a 660 nm laser irradiation
(Green-the fluorescence of SOSG after reacted with 1O2).
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Figure 3.7 The uptake of nanoparticles in UMSCC 22A cells. FACS of UMSCC
22A cells treated with free Pc 4, Pc 4 GoMe and MBA Pc 4 GoMe at 37 °C for
0.5 h (A), 1 h (B), and 2 h (C). FACS of UMSCC 22A cells treated with free Pc 4,
Pc 4 GoMe and MBA Pc 4 GoMe at 4 °C for 0.5 h (D), 1 h (E), and 2 h (F). (G)
Confocal microscopy images of Pc 4, Pc 4 GoMe or MBA-Pc 4 GoMe in UMSCC
22A cells. Hoechst 33342 (blue), Pc 4 (red).
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Figure 3.9 Cytotoxic effect of MBA Pc 4 GoMe coupled with PDT and PTT. (A-H)
Live/dead staining of UMSCC 22A cells after photoirradiation of PDT (200
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Figure 3.10 Combination therapy of PTT and PDT for UMSCC 22A head and
neck cancer in vivo. (A) Bodyweight change curves. (B) Tumor volumes change
curves. (C) Average weight of tumors in all treatments. (D) Photographs of
control mice (left mice), Pc 4 GoMe with dual laser (middle mice), MBA Pc 4
GoMe with dual laser (right mice). (E) Photos of tumors for the 6 treatment
groups.
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Figure 3.11 Histology analysis of liver and tumor of mice. (A) H&E staining of
tumor section of the mice treated with saline, Pc4 + PDT, Pc 4 GoMe + PDT, Pc
4 GoMe + dual laser, MBA Pc 4 GoMe + PDT, MBA Pc 4 GoMe + dual Laser. (B)
Liver H&E staining of liver section of mice with different treatments.

115

CHAPTER 4
Glycol chitosan mediated co-delivery of suramin and doxorubicin for the
treatment of breast cancer metastasis
ABSTRACT
Suramin (SM), an anti-angiogenesis agent, has been evaluated in various
clinical trials for cancer therapy. However, it was eventually withdrawn due to its
narrow therapeutic window and the side effects associated with multiple targets.
In this work, we developed a simple but effective system by using a non-toxic
dose of suramin together with a chemotherapeutic agents for the treatment of
metastatic triple negative breast cancer. Suramin and doxorubicin (DOX) were
encapsulated into nanoparticles by gentle gelation with glycol chitosan (GCS)
through one step preparation. The formed nanoparticles were small size and
uniform range, exhibiting a surprisingly high loading capacity of suramin. In vitro
experiments proved the effectiveness of nanoparticles in inhibiting cell migration
and invasion. The intravenous (i.v) injection of nanoparticles significantly extends
the survive rate of animals with breast cancer lung metastasis and greatly
reduces the cardiotoxicity compared to the combination of free drugs.
INTRODUCTION
Breast cancer is the most common cancer in women worldwide, while
metastasis is the major cause of human cancer death.85 Metastasis is a complex
process that involves the cell invasion from the primary tumor, intravasation and
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extravasation in circulation system, and angiogenesis and growth in the distant
location.86 Perhaps the most effective way of treating metastatic cancer is to kill
cancer cells before the dissemination from primary foci. However, the clinical
deficiency in accurately detecting small tumor mass is a limiting factor for curable
cancer treatment. When a breast cancer patient is diagnosed with distant
metastasis, the five-year relative survival rate drops from 98.6% to 23.4%.87
Currently, various treatments are available for patients with different stages of
metastasis. There is barely any FDA approved treatment other than prophylactic
and vaccination before the diagnosis of circulating tumor cells (CTC). Once a
patient is diagnosed with CTC, or even micro-metastasis, surgery or radiation
plus systemic therapy will be applied. For high risk patients, metronomic
chemotherapy and anti-angiogenesis might be necessary.86
Angiogenesis, a hallmark of malignant disease, is a process to form new
blood vessels based on the original ones, which is critical for tumor progression.
CTCs up-regulate several pro-angiogenic factors, such as vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF), to adapt to the
new tumor microenvironments.88 The combination of bevacizumab, an inhibitor of
VEGF, with paclitaxel/carboplatin significantly increased the median survival
month of patients diagnosed with metastatic colorectal cancer or advanced
NSCLC in a phase III trial.89 However, for patients with the late stage of breast
cancer, the best treatment so far only provides survival advantages of a few
months.90
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One of the major targets for anti-angiogenesis is the FGF family. FGFs
and their receptors play crucial roles in many fundamental processes from
embryogenesis to adult life, such as proliferation, differentiation, migration,
angiogenesis and wounding healing.91 Like many other mitogens, FGFs act like a
double-edged sword and deregulation of the signaling causes various types of
human cancer that arises in different tissues including lung, breast, ovarian and
prostate.91a, 92 Therefore, FGF/FGFRs have been extensively studied as a
potential target for cancer treatment. Many selective or non-selective
pharmaceutical inhibitors for FGFs and FGFRs have been developed for cancer
treatment.93
Suramin, a polysulfonated naphthylurea that inhibits VEGF and bFGF, is
reported as an anti-angiogenesis agent.94 Suramin reversed the FGF induced
drug resistance at the concentration of 1-17 µM in human prostate PC3 cells in
the presence of doxorubicin (DOX).94f The combination of suramin and various
chemotherapeutic agents have proven effective in various mice models and
entered clinical trials. The combination of suramin and paclitaxel inhibited the
brain metastatic cancer by injecting suramin at 10 mg/kg and PTX at 10
mg/ml.94h The nontoxic dose of suramin with DOX were suggested for the
treatment of prostate cancer.94f, 95 The co-delivery of suramin enhanced the
activity of DOX in dogs with spontaneous cancers.96 In the xenograft prostate
mouse model, the addition of suramin to DOX inhibited tumor growth by 60%.94f
Although suramin has a direct effect on cancer cells, high dose of suramin not
only cause cytotoxic effects but also initiate tolerance response.97 A recent study
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showed that chemical conjugates of low molecular weight heparin and suramin
which had a higher affinity to the heparin binding domain of VEGF165, which
significantly inhibited the tumor progression in a SCC-7 tumor bearing mouse
model.94c However, this mouse model was a xenograft primary tumor model.
In this study, a simple yet effective nanoparticle system is carried out for
breast cancer lung metastasis therapy. Suramin and glycol chitosan (GCS) forms
the nanoparticle system by electrostatistic effect, and DOX is encapsulated
inside. Both suramin and GCS showed inhibitory effect on the migration and
invasion of MDA-MB-231 breast cancer cell migration. Suramin at a non-toxic
dose was able to enhance the anticancer efficacy of DOX both in vitro and in
vivo. In addition, all of the components in this system are highly biocompatible,
easy for large scale fabrication, which make this system very translatable for the
metastatic breast cancer treatment.
RESULTS
DOX encapsulated glycol chitosan/suramin (GCS-SM/DOX) NP synthesis
It has been reported that chitosan can form hydrogels with
tripolyphosphate (TPP)98 and alginate.99 Many factors can affect the size of
nanoparticles, especially the TPP to chitosan ratio, pH of the buffer and the ionic
strength of the dissolution medium.98b, 100 As anionic and cationic compounds
account for the majority weight of the delivery system, the loading capacity of
therapeutic agents will be greatly reduced if they are not an active
pharmaceutical ingredient. Moreover, a few reports showed that chitosan was
able to form the hydrogel with sodium lauryl sulfate.101 We came up with the idea
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of creating GCS-SM NPs through the gelation process between the sulfate
groups on suramin and amine groups on glycol chitosan, where suramin acted as
an anionic compartment and glycol chitosan acted as a cationic compartment
(Figure 4.1). The relationships among particle size, suramin content in the final
formulation, pH of the buffer, as well as the concentration of suramin were shown
in Figure 4.2A-D. In order to examine the effect of suramin concentration on the
nanoparticle size, we fixed the glycol chitosan concentration at 2.5 mg/mL in PBS
buffer. With the suramin concentration varying from 25% to 5% (weight ratio to
glycol chitosan), the hydrodynamic size of nanoparticle was increased from 220
nm to 277 nm along with the increased PDI (polydispersity index). Next step, we
varied the pH of the buffer from 6 to 7.4. The size of nanoparticles was
maintained at 210 nm level at pH 6. The particle size increased to 298 nm when
the buffer pH was adjusted to 7.4. Furthermore, we found that too low or too high
pH inhibited the formation of nanoparticles. In addition, within the range of 0.1 to
0.5 mg/mL, the concentration of SM did not have significant effect on
nanoparticle size. However, when the concentration of SM reached 1 mg/ mL,
nanoparticle had a final size over 600 nm with a PDI of 0.25 (Figure 4.2C). The
loading of DOX had no significantly impact on final hydrodynamic size of the
nanoparticle. With DOX loading content from 1% to 10% of chitosan, the size of
nanoparticles only slightly shifted from 186 nm to 219 nm (Figure 4.2D).
Characterization of GCS-SM/DOX NP
With the above optimized condition, we synthesized nanoparticle with SM
to chitosan ratio at 16% in pH 7.0 20 mM PBS buffer at the SM concentration of
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0.5 mg/mL SM. The final hydrodynamic size of nanoparticle was 186 nm, with a
slightly positive surface charge as shown in Figure 4.3A. Transmission electron
microscopy revealed that these nanoparticles were spherical with the average
size of 49.09±11.52 nm (Figure 4.3B). We reasoned that the highly swelling and
hydrated glycol chitosan caused the dramatically increased size of nanoparticles
in aqueous solution.
Figure 4.3C showed the release behaviors of suramin and DOX from the
nanoparticles. It was revealed that DOX and suramin shared a similar release
pattern, in which after 8 h of incubation in PBS 7.4, both the DOX and suramin
had reached the platform at around 80%. The simultaneously release pattern for
DOX and suramin ascertained the optimized ratio between two drugs to maintain
the same from the point of the preparation to the in vivo release process. Since
the complex was slightly positive, there is a concern about the colloid stability of
nanoparticles. The stability of nanoparticles was evaluated through the long-term
incubation of NPs in PBS and short term incubation of NPs supplemented with
FBS. Figure 4.3D showed that these NPs were stable and did not aggregate in
10% serum containing media. NPs were very stable in PBS environment as
evidenced by no size increase after two weeks incubation at 37ºC (Figure 4.3E).
GCS-SM/DOX NP inhibits cell migration and invasion
To investigate the effect of suramin or suramin nanoparticles on breast
cancer cell migration, wound healing assay and transwell invasion assay were
carried out. In the wound healing assay, effects of different treatments on cell
migration were analyzed by live cell imaging (Figure 4.4).
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The average speed for cell migration was measured by the wound
distance divided by the time consumed to completely heal. Figure 4.4 A and B
showed that suramin significantly inhibited cell migration and the effect was
enhanced by GCS-SM nanoparticle (Control group had an average speed of
28.17 µm/h, which was twice as fast as the group treated with suramin (Figure
4.4C). Interestingly, glycol chitosan also showed an obviously inhibiting effect on
cell migration with an average speed of 18.17 µm/h. A study showed that 100
µg/mL glycated chitosan significantly inhibited the migration of 4T1 and MDAMB-231 cells, and reasoned the cause of the inhibition was that glycated
chitosan up-regulated E-cadherin and down-regulated slug and twist 1.102 Based
on the structural similarity, we postulate that GCS has a similar (if not the same)
function as glycated chitosan. Next, we tested whether the effect of suramin and
suramin nanoparticle on cell migration was due to its cytotoxic effect. We found
that neither suramin nor GCS-SM NP inhibited cell proliferation at the
concentration up to 200 µM after 24 h treatment (Figure 4.4D), which indicates
that the inhibition of cell migration is not towing to the cytotoxic effect.
To investigate the inhibition effect of SM and GCS-SM NPs on cell
invasion, we performed a transwell invasion assay. Figure 4.5 showed that the
invaded cell number per view area was significantly decreased from 951.75 in
the control group to 718 in the group treated with 40 µM SM. GCS-SM NPs
further decreased the number to 483. Thus, we proved that SM or GCS-SM NPs
inhibited both cell migration and invasion without causing noticeable cytotoxic
effect.
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Cellular uptake of GCS-SM/DOX NPs
To measure GCS-SM/DOX NPs uptake efficiency in vitro, we treated
MDA-MB-231 cells with free drugs, free-drug combinations, and GCS-SM/DOX
NPs. After 1, 3, and 6 h of incubation, cells were analyzed by the flow cytometry
(FACS) and confocal microscopy. Figure 4.6A showed that free DOX entered
cells much slower than GCS-SM/DOX NPs: after 1h of treatment, NPs treatment
exhibited a much stronger red fluorescence signal inside cell than free DOX; after
3h, almost all of DOX that delivered by NPs was in nuclei while a lot of DOX from
free DOX treatment still stayed in cytosol. We next compared the cellular uptake
behaviors of free DOX or GCS-SM/DOX NPs at 3 h and 6 h in presence or
absence of a/b FGF using FACS (Figure 4.6B). In presence of a/b FGF, GCSSM/DOX NPs treatment showed a much better DOX uptake compared to free
DOX. Without a/b FGF treatment, no significant difference in uptake was
observed between free DOX and GCS-SM/DOX NPs treatments at 3 h and 6 h.
It’s an interesting phenomenon that a/b FGF causes the differences in DOX
uptake between GCS-SM/DOX NPs and free DOX, we reason that FGF might
induced chemo-resistance103 while suramin could sensitizer those drug resistant
cells.
Suramin and DOX have synergistic growth inhibitory effect of MDA-MB-231
cells
Suramin showed biphasic effects on the proliferation of cancer cells.104 On
one hand, as a non-specific growth factor inhibitor, it inhibits angiogenesis of the
cancer cells. On the other hand, high concentration of suramin kills cancer cells
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directly. Although it has been reported that suramin kills cancer cells in a doseand time-dependent manner,94d, 94g, 105 the cell killing mechanism is still not fully
understood.
Since SM was reported to induce the drug cross resistance against
doxorubicin and amsacrine at high concentration,106 it is crucial to find out the
ratio that keeps the combination of DOX and suramin achieving synergistic effect
while not inducing side effects. After 24 h treatment of 200 µM SM in form of
either free SM or SM NPs, no cytotoxicity was observed. However, after 48 h of
treatment, the IC50 of SM and SM NPs was 200 µM and 62.97 µM, respectively
(Figure 4.7B). In this study we decided to test SM at nontoxic dose (10 µM, 20
µM and 100 µM) when combined with doxorubicin. We first investigated whether
free-drug combinations at a non-toxic dose of suramin increased DOX
cytotoxicity in presence of a/b FGF or not. Figure 4.7A showed that the
cytotoxicity of DOX was greatly enhanced by the addition of 10 µM SM, but
further increase of SM concentration (20 µM or 100 µM) did not further enhance
its cytotoxicity (Figure 4.7A)
SM was reported to enter human micro vascular endothelial cells through
an active process involving caveolae system,107 where the zwitterionic
nanoparticle may enter cell membrane through membrane penetration.108 We
reasoned that the synergistic effect was caused by the delivery of SM. To
optimize the synergistic effect, different ratios of GCS-SM NPs to DOX were
tested in MDA-MB-231 cells. The results in Figure 4.7C showed that synergistic
growth inhibitory effects were observed at relatively low ratio of suramin to DOX
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(Additive effect with CI = 1, synergism with CI < 1, and antagonism with CI > 1).49
We further created a profile of synergistic growth inhibition of MDA-MB-231 cells
under different concentrations of SM at 3 GCS-SM/DOX ratios (Figure 4.7D).
GCS-SM/DOX NP inhibits proliferation and metastasis of cancer cells in a
tumor-bearing mouse model
Based on the in vitro results, we further tested the anti-metastatic efficacy
of GSC-SM/DOX NP in a breast cancer lung metastasis model in nude mice.
There are two mostly used methods to generate breast cancer lung metastasis
animal models, either by orthotropic implantation of cancer cells in the mammary
gland or tail vein injection of cancer cells. We applied the tail vein injection not
only because it was faster but also produced tumors mainly in lung tissue with
the similar genetic profiles.109 It was previously reported that if the treatment was
started on the first day of the cell implantation, the number of metastasis would
be greatly inhibited by the combination of chemotherapy and suramin.94h To allow
cancer cells to adapt to the new environment, we started the treatment on the
second day after cancer cell inoculation. The effect of combination treatment on
the breast cancer lung metastasis was evaluated by bioluminescence for ventral
images. Figure 4.8B showed that the high sensitivity of luminescence imaging
system and that the signal was highly correlated with cell number in the range of
125 and 8000 cells/well.
The whole body photoemission rate was measured to indicate the cell
proliferation and the progression of metastasis over the next 6 weeks (Figure
4.8.A). The results showed that in the control group MDA-MB-231 cells was
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accumulated at the stem of tail for 4 weeks and the signal for lung metastasis
was dramatically increased after week 5. For the free SM or SM-NPs treatment,
both the proliferation of cancer cells and metastasis were slowed down
compared to the control. For the free drug combination treatment, the
proliferation of cancer cells was dramatically inhibited and no detectable lung
metastasis was observed during the experimental period, while SM/DOX NPs
completely eradicated the cancer cells from it treated mice. Furthermore, the
injection of free SM, free DOX/suramin, SM NPs and GCS-SM/DOX NPs did not
cause significant weight loss (Figure 4.8C).
Kaplan-Meier survival analysis was carried out for 12 weeks (Figure
4.9A). The saline treated group showed a 100% lethal by 68 days. SM and SM
NPs treatments had moderately increased survival rates. The median survival
time for control mice was 64.5 days while for SM treatment alone reached 76.5
days. For the free combination group and GCS-SM/DOX nanoparticle group, the
median survival time was significantly improved (P=0.0038 and 0.021
respectively). The median survival time was extended to 81.5 days for free drug
combination treatment group, and for GCS-SM/DOX nanoparticle treatment
group the time was extended to higher than 85 days. After weeks 12, the free
drug combination group has the survival rate of 50% while GCS-SM/DOX NPs
group achieved 60%. As the metastatic site formed a colony instead of the
formation of discrete tumors using the method of tail vein injection,110 we further
evaluated the metastatic status of each group by measuring the lung weight
(Figure 4.9B). Neither SM nor SM NPs group showed any significant effect on
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lung weight compared to the control, while the free drug combination and the
nanoparticle combination treatments reduced lung weight by 53% (P=0.0218)
and 56% (P=0.0089), respectively.
At the end of experiment, an ex vivo organ images were obtained by
injecting luciferin i.v. to mice before they were sacrificed (Figure 4.10). Images of
the control group were taken separately due to the fact that no mice was survived
at the end of the whole experiment, but the same imaging protocol was carried
out throughout all groups. Compared to control group, other mice that were
survived till the end of the experiment showed no significantly visible
luminescence, indicating that the metastasis was highly inhibited in these mice
(Figure 4.10A and B). As injected MDA-MB-231 cells were constitutively
expressing both GFP and luciferase proteins, we were able to directly visualize
the metastatic cancer cells in the lung in GFP channel. It was found out that the
GFP expression was positively correlated with the luminescent signal shown
above, and GCS-SM/DOX NP treated mice showed the least GFP signal in the
lung (Figure 4.10C).
Evaluation of GCS-SM/DOX NP treatment by pathology analysis
DOX is an effective anticancer drug with notorious cardiotoxic effects.111 It
is suggested that the cardiotoxic effects primarily come from iron accumulation in
mitochondria and the production of ROS. The DOX-dependent cardiac damage
often results in irregular-aligned mitochondria and reduced perivascular fibrosis
and detectable by transmission electron microscopy (TEM) images.111-112
Analysis of the cardiovascular pathology by TEM revealed that the free drug
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combination treated group exhibited misaligned mitochondria (Figure 4.9C),
indicating the result of cardiotoxicity. However, no abnormal mitochondria
alignment was detected in the co-delivery of suramin and DOX by
nanoformulation.
Histologic analysis of lung and liver from each treatment was shown in
Figure 4.11. Based on the boundary between the normal and tumor tissue, we
found that the lung in control group was almost fully covered by cancer cells, and
that both free SM and SM NPs treated groups have a mild reduction in the
occupied area ratio between tumor and normal tissue size. In the free drug
combination and the GCS-SM/DOX NP groups, no visible tumor was found in
their tissue sections. There was no significant difference in histology among the
livers from all groups.
CONLCUSION
In summary, we have successfully designed an efficient tool for co-loading
anti-metastasis drug suramin and chemotherapeutic drug DOX with high loading
content. At non-toxic dose of suramin, GCS-SM NPs were able to reduce the
migration speed as well as invaded cells by half. In vivo experiment showed
GCS-SM/DOX nanoparticle can greatly inhibit breast cancer lung metastases
and improve the survival time for mice without causing cardiotoxicity.
MATERIALS AND METHODS
Materials
Glycol chitosan, suramin sodium salt, doxorubicin hydrochloride and eosin
Y were purchased from Sigma. Acidic fibroblast growth factor (aFGF) and basic
fibroblast factor were purchased from Peprotech. Nuclei Isolation Kit: nuclei EZ
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prep was obtained from Sigma. Bradford protein assay kit was purchased from
Bio-Rad. Luciferin was obtained from Merck Millipore. Gill’s Hematoxylin No.2
was purchased from VWR.
Preparation of GCS-SM NPs
GCS-SM NPs were prepared by the mild ionic gelation technique between
the sulfate groups in suramin and amine group in glycol chitosan. Different
suramin concentration or amount, gelation solution pH, and doxorubicin were
investigated, respectively. Typically, glycol chitosan was dissolved in PBS pH 7.0
buffer with an ionic strength at 20 mM to achieve the concentration of 2.4 mg/mL.
Suramin was dissolved in the same buffer at the concentration of 0.5 mg/mL.
Doxorubicin hydrochloride was dissolved in ddH2O at 1 mg/mL. One and a half
milliliter of suramin solution prepared above was mixing with doxorubicin solution
first, and then injected slowly to 2.5 mL glycol chitosan solution at 0.2 mL/min
with a microinjection pump (Harvard apparatus) under stirring (400 rpm) at room
temperature. The mixture was stirred for 30 mins to allow the formation of
nanoparticles. Afterwards, the mixture was centrifuged at 3000 rpm for 5 mins
and large aggregates were removed. Nanoparticles were lyophilized with 1%
trehalose (w/w) and stored at 4ºC prior to use.
The size and surface charge (ξ-potential) of the complexes were
measured using a Zetasizer Nano-ZS (Malvern, UK) at pH 7.4. The morphology
of the GCS-SM NPs was observed by transmission electron microscopy (Hitachi
H-800 TEM) using a formvar/carbon coated Copper Grids (Electron Microscopy
Science). The original complexes solution was dropped on a grid, washed with
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ddH2O (3 ×) to remove the remaining salt, and dried with a tissue paper.
Doxorubicin concentration and suramin concentration were determined by UVVis spectrometer (Beckman, DU650) at 480 nm and 312 nm respectively.
Release kinetics and colloid stability of GCS-SM NPs
Two milliliter of GCS-SM NPs were loaded in the dialysis bags (MWCO: 68 KDa, Spectrum laboratories) and were put into 25 mL of pH 7.4,100 mM PBS
at 37 °C under continually stirring. At predesigned time, 1 mL sample was taken
and supplemented with 1 mL corresponding fresh medium. Samples were
determined by UV-Vis spectrometer. All experiments were carried out in triplicate
independently.
Nanoparticles were suspended in PBS 7.4 supplemented with different
amounts of fetal bovine serum (FBS), ranging from 10% to 50% of FBS, at the
final concentration of suramin at 100 µM at 37 °C. Nanoparticles size was
measured at pre-determined time points with DLS.
Quantification of cellular uptake of GCS-SM NPs
Cellular uptake of GCS-SM NPs was quantified by flow cytometry and
confocal microscopy. MDA-MB-231 cells were seeded in 12 well plates at
200,000 cells per well and treated with doxorubicin or GCS-SM/DOX NPs at the
DOX concentration of 1 µM for 3 h. Afterwards, cells were washed 3 times with
cold PBS to remove un-bounded doxorubicin or nanoparticles. Cells were
collected and fixed in 4% formaldehyde, and examined by FACS.
To further investigate the uptake behaviors of nanoparticles, confocal
microscopy was applied and used to monitor the uptake. MDA-MB-231 cells
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were seeded in the petri dishes and different treatment groups were then added
into each petri dish at the Dox concentration of 1 µg/mL. After 3 h co-incubation,
cells were washed for 3 times and images were taken with Zeiss 710 LM.
Wound healing assay
The migration of breast cancer cell was evaluated with a wound healing
assay. Living videos of cell migration in a 24 well plate were obtained with Zeiss
confocal microscopy. Cells were pretreatment with a/b FGF and the wound was
created by scraping the cell monolayer in a straight line with a p200 tip, and cell
debris were removed by three time washing with PBS. Cells were incubated with
different treatments and were allowed to grow in 37ºC chamber with 5% CO2
condition for 24 h.
Transwell invasion assay
Cells were seeded with BD cell culture insert with the pore size of 8 µm
(BD, Biosciences). The inserts were pre-coated with Matrigel at 0.2 mg/mL for 50
µL (dilution from BD Matrigel stock 10 mg/mL with coating buffer). Cells were
seeded at 200,000 per 50 µL in the inserts in FBS free DMEM media. Suramin or
GCS-SM NPs was then added to the inserts in 50 µL serum free medium. Lower
chamber was added with 2 mL 10% FBS DMEM containing different treatments.
After 16 h, the inserts were washed with PBS, fixed in 4% formaldehyde, and
permeablized with methanol. Subsequently, cells were stained with hematoxylin
and washed twice with PBS. The membrane in the inserts were then cut and
mounted on the coverslip, and the cell number was counted with a light
microscopy under 10 × magnification. Each well was imaged on 5 different fields,

131

and the invasion rate was expressed by the average number of cells per
microscopic field.
Cell viability assay
The anticancer activities of the combination of DOX and suramin was first
investigated with MTT assay. Two cell lines, MDA-MB-231 and MDA-MB-231
pre-incubated with a/b FGF, were treated with DOX, suramin and the
combination of DOX with Suramin at 10 to 50 µM. Cells were seeded in 96-well
plates at an initial density of 20,000 cells/well in 150 mL of DMEM medium
supplemented with 100 U penicillin/streptomycin and 10% FBS. After 24 h of
incubation, the medium was replaced with 150 µL of fresh medium containing
different treatments and incubated for another 48 h. Afterwards, the media were
replaced with 100 µL fresh media containing 1 mg/mL MTT reagent and
incubated for another 4 h. The formed MTT crystal was dissolved with a stop
solution and the finally optical density of the medium was measured using a
microplate reader (ELX808, Bio-Tech Instrument, Inc) at λ = 595 nm.
In vivo experiment
All animal experiments were conducted in accordance with NIH
regulations and approved by the Institutional Animal Care and Use Committee of
the University of South Carolina. Female athymic mice at 6 to 8 weeks (nu/nu)
were obtained from Jackson laboratory. MDA-MB-231-Luc-GFP cells were
implanted by tail vein injecting 100 µL cell suspension (2×106). Mice were then
randomly divided into 5 groups: 1) mice were treated with saline only; 2) Mice
were treated with suramin at dose of 3.5 mg/kg once per week; 3) Mice were
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treated with suramin and Doxorubicin at dose of 3.5 mg/kg of suramin and 0.5
mg/kg of Doxorubicin once per week; 4) mice were treated with GCS-SM NPs at
the dose of 3.5 mg/kg once per week; 5) mice were treated with GCS-SM/DOX
NPs at the equivalent dose once per week. The whole treatment procedure
lasted for two months and the progression of tumor cells were monitored the
luminescence with IVIS Lumia system by i.v. injection of luciferin (30 mg/mL, 50
µL) every week. Bodyweight of mice were measured every week. At the endpoint
of each mouse, all the organs were isolated and lung weight was measured.
Fluorescent images of lungs were also taken. Isolated organs were fixed in 10%
neutralized formalin solution and embedded in paraffin. Tumor was sliced into 5
µm thickness and followed with standard H&E staining protocol.
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Figure 4.1 Illustration of the fabrication of GC-SM/DOX NPs.
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Figure 4.2 (A) The effects of SM amount, (B) pH of the buffer, (C) SM
concentration, (D) and the loading content of DOX on the hydrodynamic size and
PDI (Black column-hydrodynamic size, red column-PDI).
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Figure 4.3 Characterization of GCS-SM NP. (A) Hydrodynamic size measure by
DLS and surface charge measured by Zeta sizer. (B) Transmission electron
microscopy images of GCS-SM/DOX NPs with 20 K and 100 K magnification,
respectively. (Left) 20 K magnification, (Right) 100 K magnification. Scale bar:
200 nm and 50 nm. (C) In vitro release of suramin and doxorubicin in PBS. (D)
Hydrodynamic size of GCS-SM NPs when co-incubated with 10%-30% FBS
medium. (E) Long-term stability GCS-SM NPs in PBS.
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Figure 4.4 The effect of GCS-SM NP on the migration of MDA-MB-231 cells. (A)
Photographs of cell migration after treated with SM, GCS or GCS-SM NP at
different concentrations through a living cell imaging. Scale bar: 50 µm. (B)
Quantification of migration distance of each time point. (C) Average migration
speed of each treatment groups. (D) Cytotoxicity of SM or SM NPs toward MDAMB-231 cells for 24 h.
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Figure 4.5 Cell invasion inhibitory effect. (A) Representative images of cells
treated with SM or GCS-SM NPs at different concentrations. (B) Cell counting
result after 16 h invasion study. (N=5 pictures per treatment, ** P<0.01).
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Figure 4.6 The uptake of nanoparticles in MDA-MB-231 cells. (A) Confocal
microscopy images of MDA-MB-231 cells after treating with DOX or GCSSM/DOX NP for 3 h. Blue-Hoechst 33342, red-DOX. (B) FACS of MDA-MB-231
cells treated with free DOX or GCS-SM/DOX NP for 3 h or 6 h. (Left: cells treated
with a/b FGF, Right: cells without treatment of a/b FGF)
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Figure 4.7 Synergistic effect of DOX and GCS-SM NPs in MDA-MB-231 cells.
(A) Cell viability of DOX in combination with suramin at different concentration.
(B) The cytotoxicity of Suramin and SM NP after 48 h treatment. (C) CI index
calculation of DOX and GCS-SM NPs mixing at different ratio. (D) Cell viability of
combinational nanoparticles at different ratio.
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Figure 4.8 The inhibitory effect of GCS-SM/DOX NP on tumor growth in vivo
using bioluminescence assay. (A) Luminescence images of mice in different
treatments from week 1 to week 6. (B) Cell luminescence as a function of cell
number. (C) Mice body weight change curves over the experiment.
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Figure 4.9 GCS-SM/DOX NP increased survival rate and reduced side effects.
(A) Survive curves of different treatments, (B) lung weight in different treatments,
(C) and the transmittance electron microscopy images of heart tissues from
control, GCS-SM/DOX NP, and the free drug combination treatment groups. (*
P<0.05, ** P<0.01)
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Figure 4.10 Evaluation of GCS-SM/DOX NP effect using ex vivo imaging. (A) Ex
vivo images of different organs, (B) open chest mice, (C) and the fluorescent
images of lungs in different treatment groups.
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Figure 4.11 Histology analysis of lung and liver of mice. (H&E staining and
arrows point at the tumor area)
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CHAPTER 5
Outlook for the future development of multifunctional nanocarriers for
cancer therapy
There has been a boost in developing nanocarrier-based therapies for
treating cancer or other diseases during the past decades. In addition of
selectively accumulating in tumors through EPR effect, nanocarriers enhance the
bioavailability of poor soluble compounds. In order to fully exploit the technology
and improve safety in clinical application, we developed two types of nanocarriers: 1) glycol chitosan based nanomedicine; 2) gold nanoparticles gated
mesoporous silica nanoparticles.
We first developed an environment-sensitive peptide delivery system, dual
secured nano-sting (DSNS), through the combination of a zwitterionic glycol
chitosan and disulfide bonds. It released drug only if it went through the
environment that had both acidic and reducing conditions. To further take
advantage of this electrostatic system, we built the co-delivery system by which
the suramin and DOX were delivered at the optimized ratio and with high loading
efficiency in this nano-formulation. Suramin can act as a dual functional agent,
for which it can act as a crosslinking agent as well as an angiogenesis inhibitor.
The new nanoparticle was able to improve the median survival time of mice with
breast cancer lung metastasis and reduced cardiocytotoxicity. To further
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elaborate this combination effect in vivo, it will be beneficial to build an animal
model where the metastasis process is induced in a different way. Instead of the
tail vein injection of MDA-MB-231-GFP-Luc cells into nude mice, 4T1-Luc cells
can be injected through the orthotopic implantation of in Balb/c mice. The
orthotopic implantation exhibits a higher similarity with human metastasis
process by controlling the direction of tumor progression from primary tumor to
lung metastasis, and also makes it possible to investigate the effect of GCSSM/DOX NP in inhibiting primary tumor.
In addition, we fabricated gold nanosphere/mesoporous silica hybrid
(GoMe) nanocarriers which are suitable for encapsulating both hydrophilic and
hydrophobic drugs. GoMe can release the encapsulated cargoes in response to
either NIR irradiation or intracellularly elevated redox potential. DOX@GoMe
coupled with NIR showed a synergistic effect compared to its components of
applying either PTT alone or DOX treated cell alone. Furthermore, 64Cu-labeled
GoMe can successfully detect the spontaneous lung tumors in a urethaneinduced lung cancer mouse model through PET imaging. However, GoMe also
showed a high accumulation in liver. In order to increase the targeting efficiency
and completely eradicate cancer cells, we developed the sigma 2 receptors
targeted GoMe for cancer photothermal therapy and photodynamic therapy. By
combining PTT and PDT, MBA Pc 4 GoMe efficiently killed UMSCC 22A and A
2058 cells. In vivo experiment established by subcutaneously injecting UMSCC
22A cells in nude mice proved that this targeting GoMe combining PTT and PDT
was able to significantly inhibit tumor progression. For the future study, it would
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be beneficial to evaluate the biodistribution of MBA Pc 4 GoMe. We expect a
higher tumor selectivity of MBA Pc 4 GoMe and lower accumulation in liver after
i.v injection. In addition, a systemic investigation of the structure–activity
relationship of MBA and sigma 2 receptor would be valuable.
Overall, various multifunctional nanocarriers are being developed in my
PhD research. By infusing the first nano-delivering system with high targeting
efficacy, the function of diagnosis, higher drug-loading capacity and versatile
drug-loading flexibility, our newer generation of nanocarriers promises to be more
efficient and practical in the era of personalized medicine.
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